<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83118</article-id><article-id pub-id-type="doi">10.7554/eLife.83118</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Common genetic variations in telomere length genes and lung cancer: a Mendelian randomisation study and its novel application in lung tumour transcriptome</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-291297"><name><surname>Cortez Cardoso Penha</surname><given-names>Ricardo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2847-1993</contrib-id><email>cortezr@iarc.who.int</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-290487"><name><surname>Smith-Byrne</surname><given-names>Karl</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292475"><name><surname>Atkins</surname><given-names>Joshua R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-87280"><name><surname>Haycock</surname><given-names>Philip C</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5001-3350</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-180562"><name><surname>Kar</surname><given-names>Siddhartha</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-240902"><name><surname>Codd</surname><given-names>Veryan</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-240903"><name><surname>Samani</surname><given-names>Nilesh J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-253157"><name><surname>Nelson</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292476"><name><surname>Milojevic</surname><given-names>Maja</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-292477"><name><surname>Gabriel</surname><given-names>Aurélie AG</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-290490"><name><surname>Amos</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-292478"><name><surname>Brennan</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-148586"><name><surname>Hung</surname><given-names>Rayjean J</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-290488"><name><surname>Kachuri</surname><given-names>Linda</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-292599"><name><surname>Mckay</surname><given-names>James D</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1787-3874</contrib-id><email>mckayj@iarc.who.int</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04q84b570</institution-id><institution>Genomic Epidemiology branch, International Agency for Research on Cancer/World Health Organization (IARC/WHO)</institution></institution-wrap><addr-line><named-content content-type="city">Lyon</named-content></addr-line><country>France</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>Cancer Epidemiology Unit, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/030qtrs05</institution-id><institution>MRC Integrative Epidemiology Unit, Bristol Population Health Science Institute, Bristol Medical School (PHS)</institution></institution-wrap><addr-line><named-content content-type="city">Bristol</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04h699437</institution-id><institution>Department of Cardiovascular Sciences, University of Leicester</institution></institution-wrap><addr-line><named-content content-type="city">Leicester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0187kwz08</institution-id><institution>NIHR Leicester Biomedical Research Centre, Glenfield Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Leicester</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff6"><label>6</label><institution>Ludwig Lausanne Branch, Faculty of Biology and Medicine</institution><addr-line><named-content content-type="city">Lausanne</named-content></addr-line><country>Switzerland</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Institute for Clinical and Translational Research, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01s5axj25</institution-id><institution>Lunenfeld-Tanenbaum Research Institute, Sinai Health</institution></institution-wrap><addr-line><named-content content-type="city">Toronto</named-content></addr-line><country>Canada</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Departament of Epidemiology and Population Health, Stanford University</institution></institution-wrap><addr-line><named-content content-type="city">Stanford</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Banovich</surname><given-names>Nicholas E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hfpnk21</institution-id><institution>Translational Genomics Research Institute</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83118</elocation-id><history><date date-type="received" iso-8601-date="2022-08-31"><day>31</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-03"><day>03</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-08-24"><day>24</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.24.22279131"/></event></pub-history><permissions><copyright-statement>© 2023, Cortez Cardoso Penha et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Cortez Cardoso Penha et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83118-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83118-figures-v1.pdf"/><abstract><sec id="abs1"><title>Background:</title><p>Genome-wide association studies (GWASs) have identified genetic susceptibility variants for both leukocyte telomere length (LTL) and lung cancer susceptibility. Our study aims to explore the shared genetic basis between these traits and investigate their impact on somatic environment of lung tumours.</p></sec><sec id="abs2"><title>Methods:</title><p>We performed genetic correlation, Mendelian randomisation (MR), and colocalisation analyses using the largest available GWASs summary statistics of LTL (N=464,716) and lung cancer (N=29,239 cases and 56,450 controls). Principal components analysis based on RNA-sequencing data was used to summarise gene expression profile in lung adenocarcinoma cases from TCGA (N=343).</p></sec><sec id="abs3"><title>Results:</title><p>Although there was no genome-wide genetic correlation between LTL and lung cancer risk, longer LTL conferred an increased risk of lung cancer regardless of smoking status in the MR analyses, particularly for lung adenocarcinoma. Of the 144 LTL genetic instruments, 12 colocalised with lung adenocarcinoma risk and revealed novel susceptibility loci, including <italic>MPHOSPH6</italic>, <italic>PRPF6</italic>, and <italic>POLI</italic>. The polygenic risk score for LTL was associated with a specific gene expression profile (PC2) in lung adenocarcinoma tumours. The aspect of PC2 associated with longer LTL was also associated with being female, never smokers, and earlier tumour stages. PC2 was strongly associated with cell proliferation score and genomic features related to genome stability, including copy number changes and telomerase activity.</p></sec><sec id="abs4"><title>Conclusions:</title><p>This study identified an association between longer genetically predicted LTL and lung cancer and sheds light on the potential molecular mechanisms related to LTL in lung adenocarcinomas.</p></sec><sec id="abs5"><title>Funding:</title><p>Institut National du Cancer (GeniLuc2017-1-TABAC-03-CIRC-1-TABAC17‐022), INTEGRAL/NIH (5U19CA203654-03), CRUK (C18281/A29019), and Agence Nationale pour la Recherche (ANR-10-INBS-09).</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>telomere length</kwd><kwd>lung cancer</kwd><kwd>GWAS</kwd><kwd>Mendelian randomisation</kwd><kwd>gene expression</kwd><kwd>Genome Stability</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002655</institution-id><institution>Terry Fox Foundation</institution></institution-wrap></funding-source><award-id>IARC Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Cortez Cardoso Penha</surname><given-names>Ricardo</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>K99CA246076</award-id><principal-award-recipient><name><surname>Kachuri</surname><given-names>Linda</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004917</institution-id><institution>Cancer Prevention and Research Institute of Texas</institution></institution-wrap></funding-source><award-id>RR170048</award-id><principal-award-recipient><name><surname>Amos</surname><given-names>Christopher</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>K99CA246076</award-id><principal-award-recipient><name><surname>Haycock</surname><given-names>Philip C</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C18281/A29019</award-id><principal-award-recipient><name><surname>Haycock</surname><given-names>Philip C</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100006364</institution-id><institution>Institut National Du Cancer</institution></institution-wrap></funding-source><award-id>GeniLuc 2017–1-TABAC-03-CIRC-1 - [TABAC 17‐022]</award-id><principal-award-recipient><name><surname>Haycock</surname><given-names>Philip C</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019346</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>INTEGRAL NIH 5U19CA203654-03</award-id><principal-award-recipient><name><surname>Haycock</surname><given-names>Philip C</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Agence Nationale pour la Recherche</institution></institution-wrap></funding-source><award-id>ANR-10-INBS-09</award-id><principal-award-recipient><name><surname>Haycock</surname><given-names>Philip C</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel Mendelian randomisation framework unravels one gene expression component, correlated with proliferation and genome stability-related features, associated with telomere length in lung adenocarcinoma tumours, which provides insights into how telomere length influences the genetic basis of lung cancer aetiology.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Telomeres are a complex of repetitive TTAGGG sequences and nucleoproteins located at the end of chromosomes and have an essential role in sustaining cell proliferation and preserving genome integrity (<xref ref-type="bibr" rid="bib10">de Lange, 2009</xref>). Telomere length progressively shortens with age in proliferative somatic cells due to incomplete telomeric regions replication (<xref ref-type="bibr" rid="bib51">Watson, 1972</xref>) and low activity of the telomerase <italic>TERT</italic> in adult cells. The shortening of the telomere length results in cell cycle arrest, cellular senescence, and apoptosis in somatic cells (<xref ref-type="bibr" rid="bib21">Harley et al., 1990</xref>). The maintenance of telomere length, which allows cancer cells to escape the telomere-mediated cell death pathways, is one feature related to the hallmarks of cancer (<xref ref-type="bibr" rid="bib20">Hanahan and Weinberg, 2011</xref>).</p><p>Telomere length appears to vary between individuals and has been studied in relation to many diseases. In observational studies, telomere length is measured as the average length of telomeric sequences in a given tissue (<xref ref-type="bibr" rid="bib35">Montpetit et al., 2014</xref>). Telomere length appears correlated across tissue types (<xref ref-type="bibr" rid="bib11">Demanelis et al., 2020</xref>), and as such, leukocyte telomere length (LTL) is generally measured in epidemiologic studies as a proxy for telomere length in other tissues. Recently, LTL has been measured in 472,174 individuals from the UK Biobank (UKBB; <xref ref-type="bibr" rid="bib7">Codd et al., 2021</xref>), and LTL was associated with multiple biomedical traits (i.e. pulmonary and cardiovascular diseases, haematological traits, lymphomas, kidney cancer, and other cancer types). Genetic analysis of LTL also revealed 138 genetic loci linked to LTL across a variety of different genes involved in telomere biology and DNA repair (<xref ref-type="bibr" rid="bib7">Codd et al., 2021</xref>).</p><p>In the context of lung cancer, genetic variants at several loci have been associated with both LTL and lung cancer risk, including variants near the <italic>TERT</italic>, <italic>TERC</italic>, <italic>OBFC1</italic>, and <italic>RTEL1</italic> genes, fundamental to telomere length maintenance (<xref ref-type="bibr" rid="bib33">McKay et al., 2008</xref>; <xref ref-type="bibr" rid="bib50">Wang et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Rafnar et al., 2009</xref>; <xref ref-type="bibr" rid="bib25">Kachuri et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">McKay et al., 2017</xref>). The effects of the telomere-related variants appear more relevant to lung adenocarcinoma risk than other histologic subtypes (<xref ref-type="bibr" rid="bib34">McKay et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Landi et al., 2009</xref>). Accordingly, a causal relationship between LTL and susceptibility to lung cancer was observed using Mendelian randomisation (MR) approaches (<xref ref-type="bibr" rid="bib53">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Haycock et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Kachuri et al., 2019</xref>) as well as in observational studies that have associated directly measured telomere length with risk of lung cancer (<xref ref-type="bibr" rid="bib42">Sanchez-Espiridion et al., 2014</xref>; <xref ref-type="bibr" rid="bib54">Zhang et al., 2017</xref>).</p><p>The aim of the current work was to investigate the relationship between genetically predicted LTL and lung cancer, including lung cancer histological subtypes and smoking status. To this end, we conducted genome-wide correlations, MR, and colocalisation analyses to explore the relationship between LTL and lung cancer. We additionally undertook polygenic risk score (PRS) analysis using the LTL genetic instrument to explore the influence of LTL on the demographic, clinical, and molecular features of lung adenocarcinoma tumours.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Reporting guidelines</title><p>The current study has been reported according to the STROBE-MR guidelines (Reporting Standards Document).</p></sec><sec id="s2-2"><title>Data</title><p>Genome-wide association studies (GWASs) summary statistics for lung cancer (29,239 cases and 56,450 controls) and stratified by histological subtype (squamous cell carcinoma, small-cell carcinoma, and adenocarcinoma) and smoking status (ever and never smokers) were obtained from the International Lung Cancer Consortium (ILCCO; <xref ref-type="bibr" rid="bib34">McKay et al., 2017</xref>). All analyses of LTL requiring summary statistics used results from a GWAS of LTL in 464,716 individuals of European ancestry from the UKBB (<xref ref-type="bibr" rid="bib7">Codd et al., 2021</xref>). Downstream analyses considered additional lung cancer risk factors, such as lung function and cigarette smoking. We obtained GWAS summary statistics for forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC) from a published UKBB analysis (<xref ref-type="bibr" rid="bib27">Kachuri et al., 2020</xref>). For smoking behaviour traits, we used results from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) consortium meta-analysis of cigarettes per day (continuous), smoking initiation (ever versus never), smoking cessation (successfully quit versus continuing), and age at smoking initiation (continuous; <xref ref-type="bibr" rid="bib30">Liu et al., 2019</xref>) excluding the UKBB participants. For the obesity-related traits (continuous), we used the results from the UKBB and GIANT meta-analysis of BMI (<xref ref-type="bibr" rid="bib38">Pulit et al., 2019</xref>) and waist-to-hip ratio (WHR; <xref ref-type="bibr" rid="bib38">Pulit et al., 2019</xref>), or OpenGWAS data using UKBB participants (<xref ref-type="bibr" rid="bib13">Elsworth et al., 2020</xref>) for high-density lipoprotein (HDL), triglycerides, and systolic and diastolic blood pressure. For the alcohol behaviour trait, we obtained the results from GSCAN phase 2 of drinks per week (continuous; <xref ref-type="bibr" rid="bib45">Saunders et al., 2022</xref>). Colocalisation analyses of gene expression used lung tissue expression quantitative trait loci (eQTL) summary statistics from the Genotype-Tissue Expression (GTEx) data version 8.</p><p>Analyses of molecular phenotypes were performed using 343 lung adenocarcinoma samples of European ancestry from The Cancer Genome Atlas (TCGA) cohort with germline profile, RNA-sequencing, and epidemiological data available. Genotyping and imputation of germline variants have been described elsewhere (<xref ref-type="bibr" rid="bib16">Gabriel et al., 2022</xref>). The total somatic mutation burden of TCGA samples was obtained from <xref ref-type="bibr" rid="bib12">Ellrott et al., 2018</xref>, and DNA mutational signatures were extracted and attributed, as previously described (<xref ref-type="bibr" rid="bib16">Gabriel et al., 2022</xref>). RNA-sequencing data were obtained from TCGA data portal using TCGA biolinks package in R (version 2.22.3; <xref ref-type="bibr" rid="bib8">Colaprico et al., 2016</xref>). Telomere length measurement by whole-genome sequencing (WGS-measured TL, 655 samples across cancer sites) was retrieved from <xref ref-type="bibr" rid="bib3">Barthel et al., 2017</xref>.</p><p>Tumour genomic characteristics were defined by the analyses of the TCGA data, including gene expression-based scores of telomerase activity (<xref ref-type="bibr" rid="bib3">Barthel et al., 2017</xref>) and cellular proliferation (<xref ref-type="bibr" rid="bib47">Thorsson et al., 2018</xref>), as well as the observed frequency of somatic homologous recombination-related events (represented as a homologous recombination repair deficiency score), and the average number of somatic copy number alteration within the tumours (<xref ref-type="bibr" rid="bib28">Knijnenburg et al., 2018</xref>).</p></sec><sec id="s2-3"><title>Linkage disequilibrium score regression</title><p>Genetic correlations across traits were calculated using linkage disequilibrium score regression (LDSC) by the LDSC package (v1.0.0; <xref ref-type="bibr" rid="bib4">Bulik-Sullivan et al., 2015</xref>). Linkage disequilibrium (LD) scores were generated on the 1000 Genomes Project Phase 3 reference panel with the HLA region excluded as provided by the package due to long range LD patterns. The genome-wide correlations that passed Bonferroni correction (adjusted p-values&lt;0.05) were considered statically significant.</p></sec><sec id="s2-4"><title>Mendelian randomisation</title><p>MR is a method for interrogating relationships between putative risk factors and health outcomes by using genetic variants associated with the exposure of interest, typically obtained from GWAS, as instrumental variables. Assuming that fundamental MR assumptions are satisfied, this approach can be said to identify unbiased causal estimates. The genetic instrument for LTL was defined as the set of 144 genetic variants that were genome-wide significant (p&lt;5x10<sup>–08</sup>) but not in linkage disequilibrium with each other (r<sup>2</sup>&lt;0.01) and restricted to common genetic variation (minor allele frequency &gt;1%) in European populations. Proxy variants in LD (r<sup>2</sup>&gt;0.8, whenever possible) were chosen when a genetic variant was not available in the lung cancer GWAS. Primary MR analyses were conducted using the inverse-variance method with multiplicative random-effects (<xref ref-type="bibr" rid="bib52">Yavorska and Burgess, 2017</xref>). Sensitivity analyses to horizontal pleiotropy and other violations of MR assumptions were performed using other MR estimation methods, such as weighted median, MR-Egger, contamination mixture model, MR-PRESSO, and MR-RAPS (<xref ref-type="bibr" rid="bib52">Yavorska and Burgess, 2017</xref>; <xref ref-type="bibr" rid="bib44">Sanderson et al., 2022</xref>). Multivariable MR (MVMR) methods included the inverse-variance weighted, MR-Egger, and least absolute shrinkage and selection operator (LASSO)-based methods (<xref ref-type="bibr" rid="bib52">Yavorska and Burgess, 2017</xref>; <xref ref-type="bibr" rid="bib43">Sanderson et al., 2019</xref>).</p></sec><sec id="s2-5"><title>Colocalisation methods</title><p>Unlike MR, where the goal is to assess the evidence for a causal effect of an exposure on an outcome, colocalisation is agnostic with respect to direction of effect and only assesses the probability that the two traits are affected by the same genetic variants at a given locus. Colocalisation can be viewed as a complementary approach for evaluating MR assumptions within specific genes or regions since strong evidence of colocalisation indicates overlap in genetic mechanisms affecting LTL and lung cancer. We used COLOC (v5.1.0; <xref ref-type="bibr" rid="bib48">Wallace, 2020</xref>) to estimate the posterior probability for two traits sharing the same causal variant (PP<sub>4</sub>) in a 150 kb LD window, with PP<sub>4</sub> &gt;0.70 corresponding to strong evidence of colocalisation, as previously suggested (<xref ref-type="bibr" rid="bib48">Wallace, 2020</xref>; <xref ref-type="bibr" rid="bib31">Lopes et al., 2022</xref>). Priors chosen for the colocalisation analyses were p1=10<sup>–3</sup>, p2=10<sup>–4</sup>, and p12=10<sup>–5</sup>, or approximately, a 75% prior belief that a signal will only be observed in the LTL GWAS and less than 0.01% prior belief in favour of colocalisation between the two traits at a given locus (<xref ref-type="bibr" rid="bib17">Giambartolomei et al., 2014</xref>). Conditioning and masking colocalisation methods were also used as they may identify putative shared causal variants in the presence of multiple causal variants present in a defined LD window (<xref ref-type="bibr" rid="bib49">Wallace, 2021</xref>). We present the average PP<sub>4</sub> from all methods as our posterior belief in favour of colocalisation between LTL and lung cancer risk. Multi-trait colocalisation based on a clustering algorithm was also performed using HyPrColoc (v1.0) to identify shared genetic signals with other lung cancer-related traits (<xref ref-type="bibr" rid="bib14">Foley et al., 2021</xref>).</p></sec><sec id="s2-6"><title>Principal component analysis based on RNA-sequencing data</title><p>Read counts of RNA-sequencing data were normalised within (GC-content and gene length) and between (sequencing depth) lane procedures by EDASeq R package (version 2.28.0; <xref ref-type="bibr" rid="bib40">Risso et al., 2011</xref>) and excluding low read counts. Principal component analysis was applied using singular value decomposition method, after excluding extreme outliers. Pathway analyses were conducted using Gene Set Enrichment Analysis software (GSEA, version 4.2.3; <xref ref-type="bibr" rid="bib46">Subramanian et al., 2005</xref>) on gene annotations from Gene Ontology database. Pathway analyses were restricted to the top 500 genes positively and negatively correlated with each principal component that passed multiple-testing correction (Bonferroni-adjusted p-value&lt;0.05 for 74,465 tests), which is the maximum number of genes supported by the online software.</p><p>The PRS for LTL was composed of the same 144 variants used in the MR analysis and was computed as the sum of the individual’s beta-weighted genotypes using PRSice-2 software (<xref ref-type="bibr" rid="bib6">Choi and O’Reilly, 2019</xref>). Associations were estimated per SD increase in the PRS, which was normalised to have a mean of zero across lung adenocarcinoma samples of European ancestry within the TCGA cohort. The associations between the eigenvalues of the gene expression principal components (outcome) and demographic, clinical, and genomic features related to genome stability (predictors derived from TCGA published papers and TCGA data portal, except for the DNA mutational signatures [<xref ref-type="bibr" rid="bib16">Gabriel et al., 2022</xref>]) were calculated using a multivariate linear regression model.</p></sec><sec id="s2-7"><title>Inferring PC2 gene expression signature based on RNA-sequencing data</title><p>The TCGA-lung adenocarcinoma (LUAD) tumour samples were split into training (70%, N=255) and validation (30%, N=108) datasets. Principal components analysis based on RNA-sequencing data was performed to summarise the gene expression profiles of lung adenocarcinoma tumours into five principal components in the training and validation datasets separately, as previously described (see ‘Principal component analysis based on RNA-sequencing data’ section in methods). Subsequently, we applied the partial least squares-based method called rigid transformation (<xref ref-type="bibr" rid="bib23">Hubert and Branden, 2003</xref>) to align the first five principal components in both datasets. This method compares embeddings, low-dimensional representations in both datasets, performing a slightly rotation of principal components in order to translate and match them in both training and validation datasets. To select the most informative genes of PC2 in the training dataset, RNA levels of the genes correlated with PC2 (N=3914 out of 14,893 genes, FDR &lt;0.05 for 14,893 tests) were selected as variables for the LASSO regression models. The LASSO tune parameters were chosen by resampling the training dataset (1000 bootstraps: root mean of SE=0.12 ± 0.0004, Lambda = 10 x 10<sup>–10</sup>, r<sup>2</sup>=0.99 ± 0.00007) using the tidymodels metapackage in R (v1.0.0; wrapper of glmnet). The 10 genes selected by the LASSO model were used to infer the gene expression signature of PC2 by adding up the scaled values of the log-normalised read counts of each gene multiplied by the respective LASSO regression coefficients. For validation purpose, the inferred PC2 signature was calculated in the validation dataset and compared with the observed principal components. After validation in the subset of the TCGA-LUAD cohort, the inferred PC2 signature was calculated in TCGA-LUSC dataset to compare differences between lung cancer histological subtypes.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Genome-wide genetic correlations</title><p>The design of the study is represented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. We first assessed the shared genetic basis of telomere length, lung cancer risk, and other putative lung cancer risk factors, such as smoking behaviours (age start smoking, smoking cessation, smoking initiation, and cigarettes per day) and lung function (FEV<sub>1</sub> and FVC) using genome-wide correlations (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). There was little evidence for genetic correlations by LDSC between LTL variants and lung cancer (r<sub>g</sub> = −0.01, p=0.88) or when stratified by histologic subtypes (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Increasing LTL was genetically correlated with older age at smoking initiation (r<sub>g</sub> = 0.13, p=3.0 × 10<sup>–3</sup>), and negatively correlated with smoking cessation: (r<sub>g</sub> = −0.21, p=6.9 × 10<sup>–09</sup>), smoking initiation (r<sub>g</sub> = −0.16, p=1.3 × 10<sup>–10</sup>), and cigarettes per day (r<sub>g</sub> = −0.19, p=2.1 × 10<sup>–08</sup>). Longer LTL was genetically correlated with improved lung function, as indicated by increasing values of FEV<sub>1</sub> (r<sub>g</sub> = 0.09, p=5.1 × 10<sup>–07</sup>) and FVC (r<sub>g</sub> = 0.09, p=1.1 × 10<sup>–05</sup>). To better understand the absence of genome-wide correlations between LTL and lung cancer, we visualised the Z-scores for each trait for approximately 1.2 million variants included in the LDSC analyses (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). A subgroup of variants associated with longer LTL was correlated with increased lung adenocarcinoma risk, while the subgroup of smoking-behaviour associated variants, which also conferred an increased risk of lung adenocarcinoma, tended to have lower LTL.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Genetic correlations between leukocyte telomere length (LTL) and lung cancer (LC) related traits.</title><p>(<bold>A</bold>) Heatmap representing the genetic correlation analyses (rg) for LTL across LC, histological subtypes (lung adenocarcinoma [ADE], squamous cell carcinoma [SQC], and small-cell carcinoma [SCC]), smoking propensity (cigarettes per day [CPD], smoking cessation [SmkCes], Smoking initiation [SmkInit], and age of smoking initiation [AgeSmk]), and lung function related (forced vital capacity [FVC] and forced expiratory volume [FEV1]) traits. The black star indicates correlations that passed Bonferroni correction (p&lt;4x10<sup>–04</sup>). Heritability (<bold>h<sup>2</sup></bold>) as the proportion of the phenotypic variance caused by SNPs. (<bold>B</bold>) Plot of Z-scores (ADE versus LTL), restricting to the Hapmap SNPs (~1.2 million) but excluding HLA region. Genome-wide significant SNPs (p&lt;5x10<sup>–08</sup>) for each trait were coloured (CPD in red, SmkInit in dark red, LTL in dark blue, AgeSmk in blue, SmkCes in lightblue, and not genome-wide hits for LTL or any other selected trait in white). Linear regression line was coloured in red.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Design of the study.</title><p>Upper: the leukocyte telomere length (LTL) variants were derived from the latest genome-wide association study (GWAS) in UK Biobank (UKBB) participants by Codd et al. Genome-wide correlations between LTL and lung cancer related traits were performed. Focus on a subset of LTL variants selected for Mendelian randomisation (MR) framework. Middle: selection of independent SNPs as LTL instrument for causal inference of LTL on lung cancer risk. Explore biological meaning of these variants using colocalisation methods and principal component analyses to summarise gene expression data. Bottom: calculate LTL polygenic risk score (PRS) based on the 144 SNPs and evaluate its association with principal components and epidemiological, and molecular data of lung adenocarcinoma tumours from The Cancer Genome Atlas (TCGA) dataset (TCGA-lung adenocarcinoma [LUAD]).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s3-2"><title>MR analyses</title><p>From the 490 genetic instruments associated with LTL at genome-wide significance (p&lt;5x10<sup>–08</sup>), 144 LTL genetic instruments, that explained ~3.5% of the variance in LTL, and were in low-linkage disequilibrium (r<sup>2</sup>&lt;0.01) were used in MR analysis (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>). As a sensitivity analysis, a PRS composed of these genetic instruments was associated with TL estimated from WGS in blood samples across TCGA cohorts (Beta = 0.03, 95%CI = 0.01–0.05, p=0.001) but was not associated with TL in tumour material from the same patients (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p><p>MR analyses demonstrated that longer genetically predicted LTL was associated with increased lung cancer risk (OR = 1.62, 95% CI = 1.44–1.84, p=9.91 × 10<sup>–15</sup>) (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Longer LTL conferred the largest increase in risk for lung adenocarcinoma tumours (OR = 2.43, 95% CI = 2.02–2.92, p=3.76 × 10<sup>–21</sup>), but there was limited evidence of a causal relationship for other histologic subtypes, such as squamous cell carcinoma (OR = 1.00, 95% CI = 0.84–1.19, p=0.98) and small-cell carcinoma (OR = 1.13, 95% CI = 0.87–1.45, p=0.34; <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). However, our study was underpowered to detect an association between lung small-cell carcinoma and LTL at OR of 1.13 and considering alpha type-1 error rate of 5% (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). When stratifying the analyses by smoking status, LTL was associated with lung cancer risk in both never (OR = 2.02, 95% CI = 1.45–2.83, p=3.78 × 10<sup>–05</sup>) and ever smokers (OR = 1.54, 95% CI = 1.34–1.76, p=7.75 × 10<sup>–10</sup>; <xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Evidence for negative pleiotropy (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1c</xref>) and heterogeneity (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1d</xref>) was observed for all lung cancer outcomes except for squamous cell carcinoma. However, a significant association for LTL and lung cancer risk was found for methods robust to the significant directional pleiotropy (MR-Egger: lung cancer [OR = 2.35, p=3.37 × 10<sup>–13</sup>]; lung adenocarcinoma [OR = 4.48, p=7.30 × 10<sup>–17</sup>]; never smokers [OR = 6.84, p=2.07 × 10<sup>–10</sup>]; <xref ref-type="supplementary-material" rid="supp1">supplementary file 1b</xref>). Leave-one-out analyses detected only one outlier, rs7705526 in <italic>TERT</italic>, resulting in &gt;10% change in MR effect size for associated lung cancer subtypes (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1e</xref>). MVMR analyses considering instruments related to LTL and WHR, HDL, total triglycerides, systolic blood pressure, smoking, and alcohol intake, as well as multiple traits combined, suggested that the association between LTL and lung adenocarcinoma risk is independent of smoking propensity, obesity-related, and alcohol intake-related traits (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1f, 1g</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Genetically predicted leukocyte telomere length (LTL) association with lung cancer.</title><p>Lung cancer (by histology or by smoking status) risk associations with the LTL instrument from the inverse-variance-weighted MR analyses are expressed as OR per SD increase in genetically predicted LTL. Statistically significant associations with p-values&lt;0.05 (red square). Heterogeneity is estimated by the statistic I<sup>2</sup>, tau variance of subgroups (τ<sup>2</sup>), and p-values for Cochran’s Q heterogeneity measure.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Sensitivity analysis of the genetically predicted leukocyte telomere length (LTL) Mendelian randomisation (MR) instrument.</title><p>(<bold>A</bold>) Telomere length (TL) was measured by Barthel et al. in a subset of high-confident samples from The Cancer Genome Atlas (TCGA) cohorts using whole-genome sequencing (n=655). TL was directly measured in blood and tumour samples, and log(tTL/nTL) were also obtained from several TCGA cohorts. Associations were expressed as beta estimate per SD longer LTL in log scale. p-Values&lt;0.05 (red square). Sex, age at diagnosis, cohort, and principal components of genetic ancestry (PC1-5) were used as covariates in the linear regression model. Heterogeneity is estimated by the statistic I<sup>2</sup>, tau variance of subgroups (τ<sup>2</sup>), and p-values for Cochran’s Q heterogeneity measure. (<bold>B</bold>) Power calculation by lung cancer strata considering a variance explained by the LTL instrument of 3.5% and alpha type-1 error rate of 5%.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig2-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s3-3"><title>Colocalisation analyses</title><p>We investigated whether there was evidence of shared genetic signals between LTL and lung adenocarcinoma at loci centred on the 144 genetic instruments used in MR analyses using colocalisation methods (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1h</xref>). Loci with evidence of colocalisation between LTL and lung adenocarcinoma tended to be near genes that encode telomerase subunits and its associated complex, including genetic variants at <italic>TERT</italic> (5p15.33; rs116539972, rs7705526, rs61748181, rs71593392, and rs140648021), <italic>TERC</italic> (3q26.2; rs12638862 and rs146546514), and <italic>OBFC1</italic> (10q24.33; rs9419958 and rs139122544). Several colocalised loci mapped to genes that have not been previously linked to lung cancer risk at genome-wide significant level: <italic>MPHOSPH6</italic> (16q23.3; rs2303262), <italic>PRPF6</italic> (20q13.33; rs80150989), and <italic>POLI</italic> (18q21.2; rs2276182). Other telomere maintenance genes showed limited evidence of colocalisation with lung adenocarcinoma (i.e. <italic>TERF1</italic> and <italic>PIF1</italic>). For instance, while the <italic>RTEL1</italic> locus (20q13.33: rs117238689, rs115610405, rs35640778, and rs35902944) harboured variants associated with both LTL and lung adenocarcinoma (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>), these signals appeared to be distinct and independent of each other (avg_PP3=0.999, avg_PP4=0.001; <xref ref-type="fig" rid="fig3">Figure 3A</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1h</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Colocalisation analyses for the genetic loci defined by the 144 leukocyte telomere length (LTL) variants.</title><p>(<bold>A</bold>) Distribution of the average posterior probability for shared genetic loci between LTL and lung adenocarcinoma, highlighting in orange the telomere maintenance loci that colocalised (avg_PP4≥0.70) and in blue the ones where there was limited evidence for colocalisation (avg_PP4&lt;0.70). Dashed red line represents the arbitrary avg_PP4 cutoff of 0.70. Representative stack plots for the multi-trait colocalisation results within (<bold>B</bold>) <italic>MPHOSPH6</italic> and (<bold>C</bold>) <italic>OBFC1</italic> loci, centred on a 150 kb LD window of rs2303262 and rs9419958 variants, respectively. Left Y-axis represents the –log10(p-values) of the association in the respective genome-wide association study for a given trait. The right Y-axis represents the recombination rate for the genetic loci. The X-axis represents the chromosome position. SNPs are coloured by the linkage disequilibrium correlation threshold (<bold>r2</bold>) with the query labelled SNP in European population. Sentinel SNPs within the defined LD window were labelled in each trait.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Association plots for leukocyte telomere length (LTL) and lung adenocarcinoma at <italic>RTEL1</italic> locus.</title><p>Z-score plots for genetically predicted LTL and lung adenocarcinoma risk for the four LTL variants annotated for <italic>RTEL1</italic>. The genetic variants were coloured by the linkage disequilibrium correlation threshold (<bold>r2</bold>) with the query labelled SNP in a defined LD window of 150 kb centred on the query SNP in European populations. Z-score defined as the beta estimate divided by SE for each SNPs in the respective genome-wide association study.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig3-figsupp1-v1.tif"/></fig></fig-group><p>We further evaluated whether the loci colocalised between LTL and lung adenocarcinoma also shared genetic signals with other traits related to lung cancer susceptibility (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1i</xref>). Multi-trait analyses at the 16q23.3 locus colocalised rs2303262 with <italic>MPHOSPH6</italic> expression in lung tissue, FVC and FEV<sub>1</sub>, but not with any of the traits related to smoking behaviour (p=0.72; <xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1i</xref>). We additionally identified evidence of colocalisation (p=0.74) between lung adenocarcinoma, LTL, and gene expression in lung epithelial cells for two variants at the <italic>OBFC1</italic> locus: rs139122544 and rs9419958 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1i</xref>).</p></sec><sec id="s3-4"><title>Genetically predicted LTL association with tumour features</title><p>We investigated the impact of genetically predicted LTL on lung adenocarcinoma tumour features by estimating molecular expression patterns within 343 lung adenocarcinomas tumours using principal component analysis in RNA-sequencing data. The first five components explained ~54% of the observed variance in the RNA-sequencing data (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). To explore the biological meaning of the five components, we performed pathway analyses for the top 500 genes with the highest loadings in each component (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1j</xref>, <xref ref-type="supplementary-material" rid="supp1">supplementary file 1k</xref>). Overall, the genes correlated with each component tended to be enriched for specific cell signaling pathways (PC1: RNA processing; PC2: cell-cycle; PC3: metabolic processes; PC4: immune response; PC5: cellular response to stress and DNA damage; false discovery rate &lt;5%; <xref ref-type="supplementary-material" rid="supp1">supplementary file 1l</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Associations between molecular expression patterns of lung adenocarcinoma tumours, LTL PRS, and The Cancer Genome Atlas (TCGA) features.</title><p>(<bold>A</bold>) LTL PRS association with the first five principal components based on RNA-sequencing data of lung adenocarcinomas tumours (n=343). Results are expressed as beta estimate per SD increase in genetically predicted LTL. Linear regression model adjusted by sex, age, smoking status, and PC1-5 (genetic ancestry) covariates. Statistically significant associations with p-values&lt;0.05 (red square). (<bold>B</bold>) Heatmap representing the correlations among PC2 and selected molecular features related to telomere length canonical roles. LTL = leukocyte telomere length; PRS = polygenic risk score; PC = principal component; TMB = tumour total mutation burden; HRD = homologous recombination deficiency, SBS (single base substitution DNA mutational signatures). SBS1 and SBS5 are DNA mutational signatures associated with age-related processes, and SBS4 is associated with tobacco smoking exposure. X-shaped marker to cross correlations with p-value&gt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Principal component analysis (PCA) based on RNA-sequencing data.</title><p>The RNA sequencing data from 343 primary lung adenocarcinoma tumour samples were retrieved. (<bold>A</bold>) Principal components analysis was applied to the centred log-transformed gene read counts, and the first five principal components were represented, which explained 53.5% of the variance in the gene expression for those samples. (<bold>B</bold>) The distributions of the first five principal components are represented in the density plots.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We then tested the association between the PRS composed of the 144 genetic instruments selected for MR analysis and the five components of gene expression within lung adenocarcinoma tumours (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). The LTL PRS was positively associated with the second component (PC2) of tumour expression (Beta = 0.17, 95% CI = 0.12–0.19, p=1.0 × 10<sup>–3</sup>; <xref ref-type="fig" rid="fig4">Figure 4A</xref>). In multivariate analysis, higher values of PC2 tended to be associated with patients older at diagnosis (p=0.001), female (p=0.005), being never smokers (p=0.04), and diagnosed with early-stage tumours (p=0.002; <xref ref-type="table" rid="table1">Table 1</xref>). PC2 was also highly correlated with gene expression-based measure of cell proliferation and several genomic features related to genomic stability (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). In multivariate analysis, higher values of PC2 were associated with reduced tumour proliferation (p=3.7 × 10<sup>–30</sup>), lower somatic copy number alternations (p=1.6 × 10<sup>–05</sup>), and higher tumour telomerase activity scores (p=1.6 × 10<sup>–5</sup>). Multivariate analysis also indicated that LTL PRS remained an independent predictor of PC2 when considering these genomic features (p=0.009; <xref ref-type="table" rid="table1">Table 1</xref>). It is noteworthy only nominal associations between LTL PRS and above-mentioned features and none remained statistically significant after correction for multiple testing (<xref ref-type="supplementary-material" rid="supp1">supplementary file 1m</xref>). We next inferred the gene expression signature of PC2, based on 10 genes informative of this component selected by the LASSO regression models, in both lung adenocarcinoma (TCGA-LUAD) and squamous cell carcinoma (TCGA-LUSC) cohorts (<xref ref-type="fig" rid="fig5">Figure 5</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The association between LTL PRS and inferred PC2 was observed in TCGA-LUAD (p=0.001) but not in TCGA-LUSC (p=0.729) cases (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The inferred PC2 signature levels were higher in TCGA-LUAD than in TCGA-LUSC (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), while higher proliferation rate (<xref ref-type="fig" rid="fig5">Figure 5C</xref>, p=1.45 × 10<sup>–141</sup>) and <italic>TERT</italic> activity (<xref ref-type="fig" rid="fig5">Figure 5D</xref>, p=1.36 × 10<sup>–20</sup>) were observed in TCGA-LUSC than in TCGA-LUAD cases. Of note, the low RNA levels of the telomere-related genes (less than five read counts), such as <italic>TERT</italic> and <italic>TERC</italic>, in both TCGA-LUAD and TCGA-LUSC tumour samples limited the direct comparison of these genes between these cohorts.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Comparing inferred PC2 gene expression signature by lung cancer histological subtypes.</title><p>(<bold>A</bold>) Leukocyte telomere length (LTL) polygenic risk score (PRS) association with the 10-gene expression signature of PC2 in lung adenocarcinoma (The Cancer Genome Atlas [TCGA]-LUAD, N=343) and squamous cell carcinoma (TCGA-LUSC, N=338) cases from TCGA dataset. Results are expressed as beta estimate per SD increase in genetically predicted LTL. Linear regression model adjusted by sex, age, and PC1-5 (genetic ancestry) covariates, PC2 signature as outcome. Statistically significant associations with -values&lt;0.05. Values per SD of (<bold>B</bold>) PC2, (<bold>C</bold>) proliferation score, and (<bold>D</bold>) telomerase/<italic>TERT</italic> activity gene expression signatures by lung cancer histological subtypes (TCGA-LUAD and TCGA-LUSC). p-Values derived from Student’s t-tests.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Generating inferred PC2 signature based on RNA-sequencing data.</title><p>(<bold>A</bold>) Workflow for the generation of the PC2 signature. Calculate principal components based on RNA-sequencing data in both The Cancer Genome Atlas (TCGA)-lung adenocarcinoma (LUAD) training (N=255, 70%) and validation (N=108, 30%) datasets and use partial least square (PLS)-based method to align principal components (upper). Select the most informative genes correlated with the observed PC2 in the training dataset using least absolute shrinkage and selection operator (LASSO) regression model and validate it in the validation set (middle). Apply the PC2 signature to the TCGA-LUSC (lung squamous cell carcinoma) and TCGA-LUAD cohorts. (<bold>B</bold>) The ranked absolute coefficients/importance of the 10 genes selected by the LASSO models. Negative coefficients in red and positive ones in blue. (<bold>C</bold>) Scatter plot for the correlations between PC2 gene expression signature and observed principal components (PC1-5) based on RNA-sequencing data in the validation set. PC1 in light blue, PC2 in red, PC3 in grey, PC4 in blue, and PC5 in salmon colours.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83118-fig5-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Association between PC2 (outcome) and lung adenocarcinoma tumour features in univariate and multivariate models (n=343).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="5">Non-molecular features</th><th align="left" valign="top" colspan="2"/></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2"><bold>Predictors</bold></td><td align="left" valign="top" colspan="2"><bold>Univariate model</bold></td><td align="left" valign="top" colspan="2"><bold>Multivariate model</bold></td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top"><bold>OR/Beta (SE</bold>)</td><td align="left" valign="top"><bold>p-value</bold></td><td align="left" valign="top"><bold>OR/Beta (SE</bold>)</td><td align="left" valign="top"><bold>p-value</bold></td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Age at diagnosis<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="char" char="plusmn" valign="top">0.17±0.05</td><td align="char" char="." valign="top">0.001</td><td align="char" char="plusmn" valign="top">0.17±0.05</td><td align="char" char="." valign="top">0.001</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Gender (male)<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="top">0.73±0.11</td><td align="char" char="." valign="top">0.005</td><td align="char" char="plusmn" valign="top">0.74±0.11</td><td align="char" char="." valign="top">0.005</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Smoking status (ever)<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="top">0.67±0.16</td><td align="char" char="." valign="top">0.013</td><td align="char" char="plusmn" valign="top">0.72±0.15</td><td align="char" char="." valign="top">0.035</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Tumour stage (late)<sup><xref ref-type="table-fn" rid="table1fn3">†</xref></sup></td><td align="char" char="plusmn" valign="top">0.67±0.13</td><td align="char" char="." valign="top">0.002</td><td align="char" char="plusmn" valign="top">0.67±0.13</td><td align="char" char="." valign="top">0.002</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top" colspan="5"><bold>Molecular features</bold></td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top" rowspan="2"><bold>Predictors</bold></td><td align="left" valign="top" colspan="2"><bold>Univariate model</bold></td><td align="left" valign="top" colspan="2"><bold>Multivariate model</bold></td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top"><bold>Beta (SE</bold>)</td><td align="left" valign="top"><bold>p-value</bold></td><td align="left" valign="top"><bold>Beta (SE</bold>)</td><td align="left" valign="top"><bold>p-value</bold></td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">LTL PRS <sup><xref ref-type="table-fn" rid="table1fn4">‡</xref></sup></td><td align="char" char="plusmn" valign="top">0.17±0.05</td><td align="char" char="." valign="top">0.001</td><td align="char" char="plusmn" valign="top">0.10±0.04</td><td align="char" char="." valign="top">0.009</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Telomerase activity</td><td align="char" char="plusmn" valign="top">–0.37±0.05</td><td align="char" char="hyphen" valign="top">9.34E-13</td><td align="char" char="plusmn" valign="top">0.25±0.06</td><td align="char" char="hyphen" valign="top">1.32E-05</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Proliferation</td><td align="char" char="plusmn" valign="top">–0.69±0.04</td><td align="char" char="hyphen" valign="top">3.30E-46</td><td align="char" char="plusmn" valign="top">–0.80±0.06</td><td align="char" char="hyphen" valign="top">3.66E-30</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Copy number alteration</td><td align="char" char="plusmn" valign="top">–0.41±0.05</td><td align="char" char="hyphen" valign="top">6.36E-16</td><td align="char" char="plusmn" valign="top">–0.23±0.05</td><td align="char" char="hyphen" valign="top">1.62E-05</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Homologous recombination deficiency</td><td align="char" char="plusmn" valign="top">–0.4±0.05</td><td align="char" char="hyphen" valign="top">8.32E-15</td><td align="char" char="plusmn" valign="top">0.12±0.06</td><td align="char" char="." valign="top">0.048</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">Tumour total mutation burden</td><td align="char" char="plusmn" valign="top">–0.28±0.05</td><td align="char" char="hyphen" valign="top">1.37E-07</td><td align="char" char="plusmn" valign="top">–0.09±0.24</td><td align="char" char="." valign="top">0.695</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">SBS1</td><td align="char" char="plusmn" valign="top">–0.18±0.05</td><td align="char" char="." valign="top">0.001</td><td align="char" char="plusmn" valign="top">0.01±0.05</td><td align="char" char="." valign="top">0.827</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">SBS4</td><td align="char" char="plusmn" valign="top">–0.24±0.05</td><td align="char" char="hyphen" valign="top">6.36E-06</td><td align="char" char="plusmn" valign="top">0.04±0.18</td><td align="char" char="." valign="top">0.814</td><td align="left" valign="top" colspan="2"/></tr><tr><td align="left" valign="top">SBS5</td><td align="char" char="plusmn" valign="top">–0.27±0.05</td><td align="char" char="hyphen" valign="top">4.84E-07</td><td align="char" char="plusmn" valign="top">0.03±0.09</td><td align="char" char="." valign="top">0.770</td><td align="left" valign="top" colspan="2"/></tr></tbody></table><table-wrap-foot><fn><p>SBS (single base substitution DNA mutational signatures); LTL = leukocyte telomere length; PC = principal component; PRS = polygenic risk score.</p></fn><fn id="table1fn2"><label>*</label><p>age of diagnosis represented as beta estimate per 1 unit of SD.</p></fn><fn id="table1fn3"><label>†</label><p>OR per 1 unit of SD.</p></fn><fn id="table1fn4"><label>‡</label><p>LTL PRS is adjusted by first five PC of genetic ancestry in the univariate model.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>The maintenance of telomere length is one of the hallmarks of cancer, being critical for cell proliferation and genome integrity (<xref ref-type="bibr" rid="bib20">Hanahan and Weinberg, 2011</xref>). Individual differences in telomere length, measured either directly or indirectly by germline determinates, have been linked with multiple diseases, including cancer susceptibility (<xref ref-type="bibr" rid="bib7">Codd et al., 2021</xref>). The measurement of LTL within the UKBB has provided a resource for the development of a more powerful set of genetic instruments that capture a greater proportion of variation in LTL compared to previous studies (<xref ref-type="bibr" rid="bib7">Codd et al., 2021</xref>). We applied genetic determinants of LTL to the largest GWAS of lung cancer to further characterise the role of telomere maintenance in lung cancer aetiology.</p><p>Using an MR analysis framework, we confirmed the previously reported relationship between genetically predicted longer LTL and increased risk of lung cancer. Our expanded genetic instrument detected systematic negative pleiotropy, which has not been observed in previous MR studies (<xref ref-type="bibr" rid="bib53">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Haycock et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Kachuri et al., 2019</xref>). Correcting for this pervasive directional bias resulted in substantially larger effects of LTL on risk of lung adenocarcinoma and lung cancer in never smokers, implying that LTL may even be more important to these phenotypes than previously estimated (<xref ref-type="bibr" rid="bib53">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib22">Haycock et al., 2017</xref>; <xref ref-type="bibr" rid="bib26">Kachuri et al., 2019</xref>). Our observations in never smokers were also supported by multivariate MR analyses where adjustment for smoking did not attenuate the effect of LTL on lung cancer susceptibility. We used MVMR analysis (<xref ref-type="bibr" rid="bib43">Sanderson et al., 2019</xref>) to assess the potential that factors, such as BMI, smoking, alcohol use, and other obesity related factors, may account for the association between LTL and lung cancer. While the influence of alternative unknown potential confounding factors cannot be excluded, the association of LTL with lung cancer risk was materially unaltered following adjustment for a range of potential confounders considered in our MVMR analyses.</p><p>Colocalisation analyses for the variants selected as the MR genetic instrument highlighted shared genetic signals between LTL and lung adenocarcinoma, including loci near genes related to telomere length maintenance (<italic>TERT</italic>, <italic>TERC</italic>, and <italic>OBFC1</italic>) and three genetic loci not previously linked to lung cancer susceptibility (<italic>POLI</italic>, <italic>PRPF6</italic>, and <italic>MPHOSPH6</italic>). The lung cancer risk allele of the <italic>MPHOSPH6</italic> sentinel variant (rs2303262) was associated with longer LTL, reduced pulmonary function, and increased <italic>MPHOSPH6</italic> gene expression in lung tissue. <italic>MPHOSPH6</italic> encodes an enzyme associated with the RNA exosome complex where it modulates RNA binding activity. <italic>PRPF6</italic> in 20q13.33 is involved in androgen binding and has been shown to promote colon tumour growth via preferential splicing of genes involved in proliferation (<xref ref-type="bibr" rid="bib1">Adler et al., 2014</xref>). <italic>POLI</italic> is a member of the Y-family of DNA damage-tolerant polymerases involved in translesion synthesis (<xref ref-type="bibr" rid="bib32">McIntyre, 2020</xref>). As part of its role in DNA repair and replication stress, <italic>POLI</italic> interacts with <italic>TP53</italic> to bypass barriers during DNA replication, which may confer a pro-survival effect to stem cells and cancer cells (<xref ref-type="bibr" rid="bib19">Guo et al., 2021</xref>).</p><p>Despite the limited evidence of colocalisation between several loci important for telomere maintenance and lung cancer, the MR analyses restricting to the non-colocalised LTL SNPs pointed out that these loci might lie in the same causal pathway of LTL and lung cancer, highlighting the heterogeneity in the genetic effects of LTL loci.</p><p>We additionally identified the relationship between genetic determinants of LTL and a specific gene expression component in lung adenocarcinoma tumours. The aspect of this component associated with longer LTL was also associated with demographic and clinical features, such as never smoking, female, and early-stage tumours compared with other lung adenocarcinoma patients, which is an interesting but not completely understood lung cancer strata. This expression component also tended to be related to genomic features related to genomically stable tumours and strikingly associated with cell proliferation score, implying that this component might be a proxy for this feature. These results appear consistent with the canonical role of telomere length in preserving genome stability and cell proliferation (<xref ref-type="bibr" rid="bib10">de Lange, 2009</xref>).</p><p>A plausible explanation for why long LTL was associated with an increased risk of lung cancer might be that individuals with longer telomeres have lower rates of telomere attrition compared to individuals with shorter telomeres. Given a very large population of histologically normal cells, even a very small difference in telomere attrition would change the probability that a given cell is able to escape the telomere-mediated cell death pathways (<xref ref-type="bibr" rid="bib2">Aviv et al., 2017</xref>). Such inter-individual differences could suffice to explain the modest lung cancer risk observed in our MR analyses. However, it is not clear why longer TL would be more relevant to lung adenocarcinoma compared to other lung cancer subtypes. A suggestion may come from our observation that longer LTL is related to genomically stable lung tumours (such as lung adenocarcinomas in never smokers and tumours with lower proliferation rates) but not genomically unstable lung tumours (such as heavy smoking related, highly proliferating lung squamous carcinomas). One possible hypothesis is that histologic normal cells exposed to highly genotoxic compounds, such as tobacco smoking, might require an intrinsic activation of telomere length maintenance at early stages of carcinogenesis that would allow them to survive, and therefore, genetic differences in telomere length are less relevant in these cells. By contrast, in more genomically stable lung tumours, where TL attrition rate is more modest, the hypothesis related to differences in TL length may be more relevant and potentially explain the heterogeneity in genetic effects between lung tumours. Alternately, we also note that the cell of origin may also differ, with lung adenocarcinoma postulated to be mostly derived from alveolar type 2 cells, the squamous cell carcinoma is from bronchiolar epithelium cells (<xref ref-type="bibr" rid="bib41">Sainz de Aja et al., 2021</xref>), possibly suggesting that LTL might be more relevant to the former.</p><p>One surprising finding from the genetic analysis was that despite the robust and large effects of LTL on lung cancer risk observed in the MR analyses, the genetic correlation between LTL and lung cancer was effectively null. The LDSC approach considers genetic variants across the entire genome, whereas the MR approach preferentially selects variants based on their association with LTL, restricting to those that achieved genome-wide significance. One possibility for the lack of genetic correlation between LTL and lung cancer is that genetic variants may differ in the direction that they influence these traits, and we used the smoking behaviour traits to exemplify that. For example, the subgroup of genetic variants noted at genome-wide significance from LTL studies was associated with increased LTL and lung cancer risk. However, the subgroup related to smoking behaviours which, in turn, are linked with increased lung cancer risk, tends to decrease LTL. If such opposing effects were widespread across the genome, it could account for the lack of genetic correlation between LTL and lung cancer estimated by LDSC and highlights the complex nature of the genetic variants that determine LTL and lung cancer risk.</p><p>Some limitations of this study should be acknowledged. A limited sample size might have limited the detection of an association between lung small-cell carcinoma and LTL. Our colocalisation approach is generally more conservative and may fail to accurately determine the posterior probability for shared genetic signals in the presence of multiple independent associations in a given locus (<xref ref-type="bibr" rid="bib24">Hukku et al., 2021</xref>), which may be a reasonable explanation for the lack of colocalisation observed at <italic>RTEL1</italic> locus, and we stress that many of the variants that are COLOC negative are likely to be associated with lung cancer. Furthermore, the relatively small sample size of the lung adenocarcinoma cohort from TCGA may have reduced the power of our study, and larger cohorts of expression profiles tumours will be necessary to validate and explore some of our findings. The potential limitations such as collider bias within the lung adenocarcinoma case only study design should also be considered.</p><p>In conclusion, we describe an association between long genetically predicted LTL and lung cancer risk, which provides insights into how telomere length influences the genetic basis of lung cancer aetiology, including never smoking and female lung adenocarcinoma, which is an enigmatic subset of lung cancer. By using a novel framework to explore the biological implications of genetically complex traits, we unravel one gene expression component, highly correlated with proliferation rate score and other genomic stability-related features, associated with LTL in lung adenocarcinoma tumours. As far as we are aware, this is the first time an association between a PRS related to an aetiological factor, such as telomere length, and a particular expression component in the lung tumours is reported. Our findings suggest that lung adenocarcinoma patients with longer LTL might have more genomically stable tumours than the ones with shorter LTL, shedding some light on telomere biology in those tumours.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Data curation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Funding acquisition, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Mendelian Randomization analyses did not require ethical approval as it used secondary, genome-wide association data from studies that obtained informed consent from all participants and ethical approval from review boards and/or ethics committees. Individual level data, accessed under accession number phs000178.v11.p8 and project application #2731, was subject to the ethnical policies that govern the Cancer Genome Atlas. These policies can be found at https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/history/policies.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables (a-m).</title><p>(a) SNPs selected as leukocyte telomere length (LTL) instrument for the Mendelian randomisation (MR) analyses. (b) MR analyses across methods for the 144 LTL SNPs. (c) Test for directional pleiotropy using MR Egger for the 144 LTL SNPs. (d) Heterogeneity tests for the 144 LTL SNPs. (e) Leave-one out analyses for the 144 LTL SNPs. (f) Multivariable MR analyses. (g) Multivariable MR analyses for LTL and lung cancer adjusting for obesity- and alcohol-related traits. (h) Summary of the colocalisation results for the LTL instrument based on 144 variants. (i) Summary of the multi-trait colocalisation results for the 12 colocalised genetic loci. (j) Top 500 genes positively correlated with the first five principal components. (k) Top 500 genes negatively correlated with the first five principal components. (l) Pathway analysis on the top 500 genes positively and negatively correlated with the first five principal components based on RNA-seq data of 343 ADE cases from The Cancer Genome Atlas (TCGA) dataset using Gene Set Enrichment Analysis (GSEA). (m) Association of LTL polygenic risk score (PRS) with the clinical and molecular features of lung adenocarcinoma tumours.</p></caption><media xlink:href="elife-83118-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83118-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Lung cancer GWAS summary statistics obtained from ILCCO can be accessed by the database of Genotypes and Phenotypes (dbGAP) under accession phs000876.v1.p1. The GWAS summary statistics for tobacco-smoking behaviors (GSCAN: <ext-link ext-link-type="uri" xlink:href="https://conservancy.umn.edu/handle/11299/201564">https://conservancy.umn.edu/handle/11299/201564</ext-link>), LTL (<ext-link ext-link-type="uri" xlink:href="https://figshare.com/s/caa99dc0f76d62990195">https://figshare.com/s/caa99dc0f76d62990195</ext-link>), and GTEx version 8 (downloaded via GTEx google cloud resource) are publicly available. Germline data of TCGA cohorts were accessed by dbGAP under accession number phs000178.v11.p8 and project application #2731. RNA-sequencing data from TCGA cohorts were retrieved from GDC open-access data portal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>) using TCGAbiolinks package in R. TCGA-related data are publicly available as described in the data section. The code for LDSC analysis is available at: <ext-link ext-link-type="uri" xlink:href="https://github.com/bulik/ldsc/wiki/Heritability-andGenetic-Correlation">https://github.com/bulik/ldsc/wiki/Heritability-andGenetic-Correlation</ext-link>. The codes used in this study for two-sample MR, colocalisation, multi-trait colocalisation, and principal component analyses are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/ricardocortezcardoso/Telomere_Length_Code">https://github.com/ricardocortezcardoso/Telomere_Length_Code</ext-link>, (<xref ref-type="bibr" rid="bib36">Penha, 2023a</xref>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:f173a1fa2257be749737ff70cb6ab1a99d775a35;origin=https://github.com/ricardocortezcardoso/Telomere_Length_Code;visit=swh:1:snp:f384d579f907421d4a850fb22aa5ec80d4d00c9c;anchor=swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2">swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2</ext-link>). Plots were created using R packages ‘meta’ (v5.5, forest plots), ‘corrplot’ (v0.92, correlation matrix), and ‘ggplot2’ (v3.3.6). The R package to generate stackplots for visualisation of the multi-trait colocalisation results is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/jrs95/gassocplot">https://github.com/jrs95/gassocplot</ext-link>, (<xref ref-type="bibr" rid="bib37">Penha, 2023b</xref>, copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:2776666d17e41041280a9474bd480c42d7717aec;origin=https://github.com/jrs95/gassocplot;visit=swh:1:snp:fa85aef5febdc1b7f8556fa537013757f6c73915;anchor=swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b">swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b</ext-link>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We would like to acknowledge the TCGA Research Network (<ext-link ext-link-type="uri" xlink:href="https://www.cancer.gov/tcga">https://www.cancer.gov/tcga</ext-link>) and the contribution of specimen donors and research groups involved in this resource. We also would like to acknowledge the ILCCO consortium, the participants of the UK biobank and GTEx project and the supporting bodies (<ext-link ext-link-type="uri" xlink:href="https://commonfund.nih.gov/GTEx">https://commonfund.nih.gov/GTEx</ext-link>), specimen donors, and research groups. This work was supported by the Institut National du Cancer (INCa) (GeniLuc 2017–1-TABAC-03-CIRC-1 - [TABAC 17‐022]), NIH/NCI, INTEGRAL NIH 5U19CA203654-03, Cancer Research UK (grant number C18281/A29019), the France Génomique National infrastructure, funded as part of the « Investissements d’Avenir » program managed by the Agence Nationale pour la Recherche (contract ANR-10-INBS-09). Christopher Amos is a Research Scholar of the Cancer Prevention Institute of Texas ( RR170048). The work of Ricardo Cortez Cardoso Penha reported in this paper was undertaken during the tenure of an IARC Postdoctoral Fellowship at the International Agency for Research on Cancer. Linda Kachuri is supported by funding from the National Institutes of Health (K99CA246076). Philip Haycock is supported by funding from Cancer Research UK (C18281/A29019).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adler</surname><given-names>AS</given-names></name><name><surname>McCleland</surname><given-names>ML</given-names></name><name><surname>Yee</surname><given-names>S</given-names></name><name><surname>Yaylaoglu</surname><given-names>M</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Cosino</surname><given-names>E</given-names></name><name><surname>Quinones</surname><given-names>G</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>E</given-names></name><name><surname>Chopra</surname><given-names>VS</given-names></name><name><surname>Haley</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Blackwood</surname><given-names>EM</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Junttila</surname><given-names>M</given-names></name><name><surname>Stephan</surname><given-names>JP</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Pau</surname><given-names>G</given-names></name><name><surname>Fearon</surname><given-names>ER</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Firestein</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An integrative analysis of colon cancer identifies an essential function for prpf6 in tumor growth</article-title><source>Genes &amp; Development</source><volume>28</volume><fpage>1068</fpage><lpage>1084</lpage><pub-id pub-id-type="doi">10.1101/gad.237206.113</pub-id><pub-id pub-id-type="pmid">24788092</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>Shay</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mutations, cancer and the telomere length paradox</article-title><source>Trends in Cancer</source><volume>3</volume><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.02.005</pub-id><pub-id pub-id-type="pmid">28718437</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barthel</surname><given-names>FP</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Martinez-Ledesma</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Amin</surname><given-names>SB</given-names></name><name><surname>Akdemir</surname><given-names>KC</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Lichtenberg</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systematic analysis of telomere length and somatic alterations in 31 cancer types</article-title><source>Nature Genetics</source><volume>49</volume><fpage>349</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1038/ng.3781</pub-id><pub-id pub-id-type="pmid">28135248</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulik-Sullivan</surname><given-names>BK</given-names></name><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Finucane</surname><given-names>HK</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>LD Score regression distinguishes confounding from polygenicity in genome-wide association studies</article-title><source>Nature Genetics</source><volume>47</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1038/ng.3211</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bycroft</surname><given-names>C</given-names></name><name><surname>Freeman</surname><given-names>C</given-names></name><name><surname>Petkova</surname><given-names>D</given-names></name><name><surname>Band</surname><given-names>G</given-names></name><name><surname>Elliott</surname><given-names>LT</given-names></name><name><surname>Sharp</surname><given-names>K</given-names></name><name><surname>Motyer</surname><given-names>A</given-names></name><name><surname>Vukcevic</surname><given-names>D</given-names></name><name><surname>Delaneau</surname><given-names>O</given-names></name><name><surname>O’Connell</surname><given-names>J</given-names></name><name><surname>Cortes</surname><given-names>A</given-names></name><name><surname>Welsh</surname><given-names>S</given-names></name><name><surname>Young</surname><given-names>A</given-names></name><name><surname>Effingham</surname><given-names>M</given-names></name><name><surname>McVean</surname><given-names>G</given-names></name><name><surname>Leslie</surname><given-names>S</given-names></name><name><surname>Allen</surname><given-names>N</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><name><surname>Marchini</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The UK Biobank resource with deep phenotyping and genomic data</article-title><source>Nature</source><volume>562</volume><fpage>203</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmid">30305743</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SW</given-names></name><name><surname>O’Reilly</surname><given-names>PF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>PRSice-2: polygenic risk score software for biobank-scale data</article-title><source>GigaScience</source><volume>8</volume><elocation-id>giz082</elocation-id><pub-id pub-id-type="doi">10.1093/gigascience/giz082</pub-id><pub-id pub-id-type="pmid">31307061</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Codd</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Allara</surname><given-names>E</given-names></name><name><surname>Musicha</surname><given-names>C</given-names></name><name><surname>Kaptoge</surname><given-names>S</given-names></name><name><surname>Stoma</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Hamby</surname><given-names>SE</given-names></name><name><surname>Braund</surname><given-names>PS</given-names></name><name><surname>Bountziouka</surname><given-names>V</given-names></name><name><surname>Budgeon</surname><given-names>CA</given-names></name><name><surname>Denniff</surname><given-names>M</given-names></name><name><surname>Swinfield</surname><given-names>C</given-names></name><name><surname>Papakonstantinou</surname><given-names>M</given-names></name><name><surname>Sheth</surname><given-names>S</given-names></name><name><surname>Nanus</surname><given-names>DE</given-names></name><name><surname>Warner</surname><given-names>SC</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Khera</surname><given-names>AV</given-names></name><name><surname>Eales</surname><given-names>J</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Di Angelantonio</surname><given-names>E</given-names></name><name><surname>Wood</surname><given-names>AM</given-names></name><name><surname>Butterworth</surname><given-names>AS</given-names></name><name><surname>Danesh</surname><given-names>JN</given-names></name><name><surname>Nelson</surname><given-names>CP</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Polygenic basis and biomedical consequences of telomere length variation</article-title><source>Nature Genetics</source><volume>53</volume><fpage>1425</fpage><lpage>1433</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00944-6</pub-id><pub-id pub-id-type="pmid">34611362</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Silva</surname><given-names>TC</given-names></name><name><surname>Olsen</surname><given-names>C</given-names></name><name><surname>Garofano</surname><given-names>L</given-names></name><name><surname>Cava</surname><given-names>C</given-names></name><name><surname>Garolini</surname><given-names>D</given-names></name><name><surname>Sabedot</surname><given-names>TS</given-names></name><name><surname>Malta</surname><given-names>TM</given-names></name><name><surname>Pagnotta</surname><given-names>SM</given-names></name><name><surname>Castiglioni</surname><given-names>I</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name><name><surname>Bontempi</surname><given-names>G</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TCGAbiolinks: an R/bioconductor package for integrative analysis of TCGA data</article-title><source>Nucleic Acids Research</source><volume>44</volume><elocation-id>e71</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv1507</pub-id><pub-id pub-id-type="pmid">26704973</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Forer</surname><given-names>L</given-names></name><name><surname>Schönherr</surname><given-names>S</given-names></name><name><surname>Sidore</surname><given-names>C</given-names></name><name><surname>Locke</surname><given-names>AE</given-names></name><name><surname>Kwong</surname><given-names>A</given-names></name><name><surname>Vrieze</surname><given-names>SI</given-names></name><name><surname>Chew</surname><given-names>EY</given-names></name><name><surname>Levy</surname><given-names>S</given-names></name><name><surname>McGue</surname><given-names>M</given-names></name><name><surname>Schlessinger</surname><given-names>D</given-names></name><name><surname>Stambolian</surname><given-names>D</given-names></name><name><surname>Loh</surname><given-names>P-R</given-names></name><name><surname>Iacono</surname><given-names>WG</given-names></name><name><surname>Swaroop</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Kronenberg</surname><given-names>F</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Next-generation genotype imputation service and methods</article-title><source>Nature Genetics</source><volume>48</volume><fpage>1284</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1038/ng.3656</pub-id><pub-id pub-id-type="pmid">27571263</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>How telomeres solve the end-protection problem</article-title><source>Science</source><volume>326</volume><fpage>948</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.1126/science.1170633</pub-id><pub-id pub-id-type="pmid">19965504</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demanelis</surname><given-names>K</given-names></name><name><surname>Jasmine</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>LS</given-names></name><name><surname>Chernoff</surname><given-names>M</given-names></name><name><surname>Tong</surname><given-names>L</given-names></name><name><surname>Delgado</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shinkle</surname><given-names>J</given-names></name><name><surname>Sabarinathan</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Ramirez</surname><given-names>E</given-names></name><name><surname>Oliva</surname><given-names>M</given-names></name><name><surname>Kim-Hellmuth</surname><given-names>S</given-names></name><name><surname>Stranger</surname><given-names>BE</given-names></name><name><surname>Lai</surname><given-names>TP</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Aguet</surname><given-names>F</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><collab>GTEx Consortium</collab><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Kibriya</surname><given-names>MG</given-names></name><name><surname>Pierce</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Determinants of telomere length across human tissues</article-title><source>Science</source><volume>369</volume><elocation-id>eaaz6876</elocation-id><pub-id pub-id-type="doi">10.1126/science.aaz6876</pub-id><pub-id pub-id-type="pmid">32913074</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ellrott</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Saksena</surname><given-names>G</given-names></name><name><surname>Covington</surname><given-names>KR</given-names></name><name><surname>Kandoth</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>C</given-names></name><name><surname>Hess</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Chiotti</surname><given-names>KE</given-names></name><name><surname>McLellan</surname><given-names>M</given-names></name><name><surname>Sofia</surname><given-names>HJ</given-names></name><name><surname>Hutter</surname><given-names>C</given-names></name><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Wheeler</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><collab>MC3 Working Group</collab><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines</article-title><source>Cell Systems</source><volume>6</volume><fpage>271</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.03.002</pub-id><pub-id pub-id-type="pmid">29596782</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Elsworth</surname><given-names>B</given-names></name><name><surname>Lyon</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Matthews</surname><given-names>P</given-names></name><name><surname>Hallett</surname><given-names>J</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name><name><surname>Palmer</surname><given-names>T</given-names></name><name><surname>Haberland</surname><given-names>V</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Haycock</surname><given-names>P</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The MRC IEU OpenGWAS Data Infrastructure</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2020.08.10.244293</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foley</surname><given-names>CN</given-names></name><name><surname>Staley</surname><given-names>JR</given-names></name><name><surname>Breen</surname><given-names>PG</given-names></name><name><surname>Sun</surname><given-names>BB</given-names></name><name><surname>Kirk</surname><given-names>PDW</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Howson</surname><given-names>JMM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>764</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20885-8</pub-id><pub-id pub-id-type="pmid">33536417</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>AAG</given-names></name><name><surname>Lipinski</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>IARCbioinfo/imputation-nf</data-title><version designator="version 1.1">version 1.1</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/IARCbioinfo/Imputation-nf">https://github.com/IARCbioinfo/Imputation-nf</ext-link></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabriel</surname><given-names>AAG</given-names></name><name><surname>Atkins</surname><given-names>JR</given-names></name><name><surname>Penha</surname><given-names>RCC</given-names></name><name><surname>Smith-Byrne</surname><given-names>K</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Voegele</surname><given-names>C</given-names></name><name><surname>Abedi-Ardekani</surname><given-names>B</given-names></name><name><surname>Milojevic</surname><given-names>M</given-names></name><name><surname>Olaso</surname><given-names>R</given-names></name><name><surname>Meyer</surname><given-names>V</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Deleuze</surname><given-names>JF</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Mukeriya</surname><given-names>A</given-names></name><name><surname>Swiatkowska</surname><given-names>B</given-names></name><name><surname>Janout</surname><given-names>V</given-names></name><name><surname>Schejbalová</surname><given-names>M</given-names></name><name><surname>Mates</surname><given-names>D</given-names></name><name><surname>Stojšić</surname><given-names>J</given-names></name><name><surname>Ognjanovic</surname><given-names>M</given-names></name><collab>the ILCCO consortium</collab><name><surname>Witte</surname><given-names>JS</given-names></name><name><surname>Rashkin</surname><given-names>SR</given-names></name><name><surname>Kachuri</surname><given-names>L</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Kar</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Sertier</surname><given-names>A-S</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Viari</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Foll</surname><given-names>M</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genetic analysis of lung cancer and the germline impact on somatic mutation burden</article-title><source>JNCI</source><volume>114</volume><fpage>1159</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1093/jnci/djac087</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giambartolomei</surname><given-names>C</given-names></name><name><surname>Vukcevic</surname><given-names>D</given-names></name><name><surname>Schadt</surname><given-names>EE</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Plagnol</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title><source>PLOS Genetics</source><volume>10</volume><elocation-id>e1004383</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1004383</pub-id><pub-id pub-id-type="pmid">24830394</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>GTEx Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The gtex consortium atlas of genetic regulatory effects across human tissues</article-title><source>Science</source><volume>369</volume><fpage>1318</fpage><lpage>1330</lpage><pub-id pub-id-type="doi">10.1126/science.aaz1776</pub-id><pub-id pub-id-type="pmid">32913098</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Rall-Scharpf</surname><given-names>M</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Wiesmüller</surname><given-names>L</given-names></name><name><surname>Biber</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>P53 isoforms differentially impact on the POLι dependent DNA damage tolerance pathway</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>941</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-04224-3</pub-id><pub-id pub-id-type="pmid">34645785</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harley</surname><given-names>CB</given-names></name><name><surname>Futcher</surname><given-names>AB</given-names></name><name><surname>Greider</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Telomeres shorten during ageing of human fibroblasts</article-title><source>Nature</source><volume>345</volume><fpage>458</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1038/345458a0</pub-id><pub-id pub-id-type="pmid">2342578</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Nounu</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Okoli</surname><given-names>GN</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Wade</surname><given-names>KH</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Willeit</surname><given-names>P</given-names></name><name><surname>Aviv</surname><given-names>A</given-names></name><name><surname>Gaunt</surname><given-names>TR</given-names></name><name><surname>Hemani</surname><given-names>G</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Ellis</surname><given-names>HP</given-names></name><name><surname>Kurian</surname><given-names>KM</given-names></name><name><surname>Pooley</surname><given-names>KA</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Law</surname><given-names>MH</given-names></name><name><surname>Bowdler</surname><given-names>LM</given-names></name><name><surname>Iles</surname><given-names>MM</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Worrall</surname><given-names>BB</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Spurdle</surname><given-names>AB</given-names></name><name><surname>Thompson</surname><given-names>DJ</given-names></name><name><surname>O’Mara</surname><given-names>TA</given-names></name><name><surname>Wolpin</surname><given-names>B</given-names></name><name><surname>Amundadottir</surname><given-names>L</given-names></name><name><surname>Stolzenberg-Solomon</surname><given-names>R</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Onland-Moret</surname><given-names>NC</given-names></name><name><surname>Lund</surname><given-names>E</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Gunter</surname><given-names>MJ</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Svenson</surname><given-names>U</given-names></name><name><surname>van Rij</surname><given-names>A</given-names></name><name><surname>Baas</surname><given-names>AF</given-names></name><name><surname>Bown</surname><given-names>MJ</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>van t’Hof</surname><given-names>FNG</given-names></name><name><surname>Tromp</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>GT</given-names></name><name><surname>Kuivaniemi</surname><given-names>H</given-names></name><name><surname>Elmore</surname><given-names>JR</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Mckay</surname><given-names>J</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Carreras-Torres</surname><given-names>R</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Bracci</surname><given-names>PM</given-names></name><name><surname>Neale</surname><given-names>RE</given-names></name><name><surname>Olson</surname><given-names>SH</given-names></name><name><surname>Gallinger</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>GM</given-names></name><name><surname>Risch</surname><given-names>HA</given-names></name><name><surname>Klein</surname><given-names>AP</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Freedman</surname><given-names>ND</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Maris</surname><given-names>JM</given-names></name><name><surname>Aben</surname><given-names>KK</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Vermeulen</surname><given-names>SH</given-names></name><name><surname>Wiencke</surname><given-names>JK</given-names></name><name><surname>Walsh</surname><given-names>KM</given-names></name><name><surname>Wrensch</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>T</given-names></name><name><surname>Turnbull</surname><given-names>C</given-names></name><name><surname>Litchfield</surname><given-names>K</given-names></name><name><surname>Paternoster</surname><given-names>L</given-names></name><name><surname>Standl</surname><given-names>M</given-names></name><name><surname>Abecasis</surname><given-names>GR</given-names></name><name><surname>SanGiovanni</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Mijatovic</surname><given-names>V</given-names></name><name><surname>Sapkota</surname><given-names>Y</given-names></name><name><surname>Low</surname><given-names>S-K</given-names></name><name><surname>Zondervan</surname><given-names>KT</given-names></name><name><surname>Montgomery</surname><given-names>GW</given-names></name><name><surname>Nyholt</surname><given-names>DR</given-names></name><name><surname>van Heel</surname><given-names>DA</given-names></name><name><surname>Hunt</surname><given-names>K</given-names></name><name><surname>Arking</surname><given-names>DE</given-names></name><name><surname>Ashar</surname><given-names>FN</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Woo</surname><given-names>D</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Comeau</surname><given-names>ME</given-names></name><name><surname>Brown</surname><given-names>WM</given-names></name><name><surname>Silverman</surname><given-names>EK</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Hui</surname><given-names>J</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><name><surname>Thompson</surname><given-names>PJ</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><name><surname>Felix</surname><given-names>JF</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>Christiano</surname><given-names>AM</given-names></name><name><surname>Petukhova</surname><given-names>L</given-names></name><name><surname>Betz</surname><given-names>RC</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Thompson</surname><given-names>SD</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Fingerlin</surname><given-names>T</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Cotch</surname><given-names>MF</given-names></name><name><surname>Jensen</surname><given-names>RA</given-names></name><name><surname>Munz</surname><given-names>M</given-names></name><name><surname>Dommisch</surname><given-names>H</given-names></name><name><surname>Schaefer</surname><given-names>AS</given-names></name><name><surname>Han</surname><given-names>F</given-names></name><name><surname>Ollila</surname><given-names>HM</given-names></name><name><surname>Hillary</surname><given-names>RP</given-names></name><name><surname>Albagha</surname><given-names>O</given-names></name><name><surname>Ralston</surname><given-names>SH</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Shu</surname><given-names>X-O</given-names></name><name><surname>Reis</surname><given-names>A</given-names></name><name><surname>Uebe</surname><given-names>S</given-names></name><name><surname>Hüffmeier</surname><given-names>U</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Otowa</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Hibberd</surname><given-names>ML</given-names></name><name><surname>Davila</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>G</given-names></name><name><surname>Siminovitch</surname><given-names>K</given-names></name><name><surname>Bei</surname><given-names>J-X</given-names></name><name><surname>Zeng</surname><given-names>Y-X</given-names></name><name><surname>Försti</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Landi</surname><given-names>S</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>Ellinghaus</surname><given-names>D</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Noth</surname><given-names>I</given-names></name><name><surname>Ma</surname><given-names>S-F</given-names></name><name><surname>Foo</surname><given-names>JN</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J-W</given-names></name><name><surname>Cox</surname><given-names>DG</given-names></name><name><surname>Delattre</surname><given-names>O</given-names></name><name><surname>Mirabeau</surname><given-names>O</given-names></name><name><surname>Skibola</surname><given-names>CF</given-names></name><name><surname>Tang</surname><given-names>CS</given-names></name><name><surname>Garcia-Barcelo</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>K-P</given-names></name><name><surname>Su</surname><given-names>W-H</given-names></name><name><surname>Chang</surname><given-names>Y-S</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name><name><surname>Wade</surname><given-names>TD</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Cha</surname><given-names>P-C</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kimura</surname><given-names>M</given-names></name><name><surname>Hwang</surname><given-names>S-J</given-names></name><name><surname>Hunt</surname><given-names>S</given-names></name><name><surname>Spector</surname><given-names>T</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Manichaikul</surname><given-names>AW</given-names></name><name><surname>Barr</surname><given-names>RG</given-names></name><name><surname>Kahali</surname><given-names>B</given-names></name><name><surname>Speliotes</surname><given-names>E</given-names></name><name><surname>Yerges-Armstrong</surname><given-names>LM</given-names></name><name><surname>Cheng</surname><given-names>C-Y</given-names></name><name><surname>Jonas</surname><given-names>JB</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Fogh</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Powell</surname><given-names>JF</given-names></name><name><surname>Rice</surname><given-names>K</given-names></name><name><surname>Relton</surname><given-names>CL</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><collab>Telomeres Mendelian Randomization Collaboration</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Association between telomere length and risk of cancer and non-neoplastic diseases: a mendelian randomization study</article-title><source>JAMA Oncology</source><volume>3</volume><fpage>636</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.5945</pub-id><pub-id pub-id-type="pmid">28241208</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubert</surname><given-names>M</given-names></name><name><surname>Branden</surname><given-names>KV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Robust methods for partial least squares regression</article-title><source>Journal of Chemometrics</source><volume>17</volume><fpage>537</fpage><lpage>549</lpage><pub-id pub-id-type="doi">10.1002/cem.822</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hukku</surname><given-names>A</given-names></name><name><surname>Pividori</surname><given-names>M</given-names></name><name><surname>Luca</surname><given-names>F</given-names></name><name><surname>Pique-Regi</surname><given-names>R</given-names></name><name><surname>Im</surname><given-names>HK</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Probabilistic colocalization of genetic variants from complex and molecular traits: promise and limitations</article-title><source>American Journal of Human Genetics</source><volume>108</volume><fpage>25</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2020.11.012</pub-id><pub-id pub-id-type="pmid">33308443</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachuri</surname><given-names>L</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Boutron-Ruault</surname><given-names>M-C</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Quirós</surname><given-names>JR</given-names></name><name><surname>Sieri</surname><given-names>S</given-names></name><name><surname>Travis</surname><given-names>RC</given-names></name><name><surname>Weiderpass</surname><given-names>E</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Wilkens</surname><given-names>L</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Tworoger</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Field</surname><given-names>JK</given-names></name><name><surname>Marcus</surname><given-names>MW</given-names></name><name><surname>Davies</surname><given-names>MPA</given-names></name><name><surname>Hyde</surname><given-names>R</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Severi</surname><given-names>G</given-names></name><name><surname>Giles</surname><given-names>GG</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>McLaughlin</surname><given-names>JR</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Fehringer</surname><given-names>G</given-names></name><name><surname>Zong</surname><given-names>X</given-names></name><name><surname>Denroche</surname><given-names>RE</given-names></name><name><surname>Zuzarte</surname><given-names>PC</given-names></name><name><surname>McPherson</surname><given-names>JD</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci</article-title><source>Carcinogenesis</source><volume>37</volume><fpage>96</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgv165</pub-id><pub-id pub-id-type="pmid">26590902</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachuri</surname><given-names>L</given-names></name><name><surname>Saarela</surname><given-names>O</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Diergaarde</surname><given-names>B</given-names></name><name><surname>Lagiou</surname><given-names>P</given-names></name><name><surname>Macfarlane</surname><given-names>GJ</given-names></name><name><surname>Aldrich</surname><given-names>MC</given-names></name><name><surname>Tardón</surname><given-names>A</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Olshan</surname><given-names>AF</given-names></name><name><surname>Weissler</surname><given-names>MC</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Ness</surname><given-names>AR</given-names></name><name><surname>Bickeböller</surname><given-names>H</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Field</surname><given-names>JK</given-names></name><name><surname>Teare</surname><given-names>MD</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>van der Heijden</surname><given-names>EHFM</given-names></name><name><surname>Carroll</surname><given-names>JC</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name><name><surname>Zienolddiny</surname><given-names>S</given-names></name><name><surname>Skaug</surname><given-names>V</given-names></name><name><surname>Wünsch-Filho</surname><given-names>V</given-names></name><name><surname>Tajara</surname><given-names>EH</given-names></name><name><surname>Ayoub Moysés</surname><given-names>R</given-names></name><name><surname>Daumas Nunes</surname><given-names>F</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Eluf-Neto</surname><given-names>J</given-names></name><name><surname>Lacko</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>WHM</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Andrew</surname><given-names>AS</given-names></name><name><surname>Franceschi</surname><given-names>S</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Manjer</surname><given-names>J</given-names></name><name><surname>Arnold</surname><given-names>S</given-names></name><name><surname>Lazarus</surname><given-names>P</given-names></name><name><surname>Mukeriya</surname><given-names>A</given-names></name><name><surname>Swiatkowska</surname><given-names>B</given-names></name><name><surname>Janout</surname><given-names>V</given-names></name><name><surname>Holcatova</surname><given-names>I</given-names></name><name><surname>Stojsic</surname><given-names>J</given-names></name><name><surname>Mates</surname><given-names>D</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Boccia</surname><given-names>S</given-names></name><name><surname>Lesseur</surname><given-names>C</given-names></name><name><surname>Zong</surname><given-names>X</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mendelian randomization and mediation analysis of leukocyte telomere length and risk of lung and head and neck cancers</article-title><source>International Journal of Epidemiology</source><volume>48</volume><fpage>751</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy140</pub-id><pub-id pub-id-type="pmid">30059977</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kachuri</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Rashkin</surname><given-names>SR</given-names></name><name><surname>Graff</surname><given-names>RE</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Manem</surname><given-names>V</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Shete</surname><given-names>SS</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Aldrich</surname><given-names>MC</given-names></name><name><surname>Tardón</surname><given-names>A</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Bickeböller</surname><given-names>H</given-names></name><name><surname>Field</surname><given-names>JK</given-names></name><name><surname>Davies</surname><given-names>MP</given-names></name><name><surname>Dawn Teare</surname><given-names>M</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name><name><surname>Zienolddiny</surname><given-names>S</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>I</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Andrew</surname><given-names>AS</given-names></name><name><surname>Manjer</surname><given-names>J</given-names></name><name><surname>Lazarus</surname><given-names>P</given-names></name><name><surname>Arnold</surname><given-names>S</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Emami</surname><given-names>NC</given-names></name><name><surname>Warkentin</surname><given-names>MT</given-names></name><name><surname>Brhane</surname><given-names>Y</given-names></name><name><surname>Obeidat</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>RM</given-names></name><name><surname>Relton</surname><given-names>C</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Haycock</surname><given-names>PC</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Witte</surname><given-names>JS</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immune-mediated genetic pathways resulting in pulmonary function impairment increase lung cancer susceptibility</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13855-2</pub-id><pub-id pub-id-type="pmid">31911640</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knijnenburg</surname><given-names>TA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zimmermann</surname><given-names>MT</given-names></name><name><surname>Chambwe</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Way</surname><given-names>GP</given-names></name><name><surname>Greene</surname><given-names>CS</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Jia</surname><given-names>P</given-names></name><name><surname>Shinbrot</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Monnat</surname><given-names>RJ</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas</article-title><source>Cell Reports</source><volume>23</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.076</pub-id><pub-id pub-id-type="pmid">29617664</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Goldin</surname><given-names>LR</given-names></name><name><surname>Goldstein</surname><given-names>AM</given-names></name><name><surname>Rotunno</surname><given-names>M</given-names></name><name><surname>Mirabello</surname><given-names>L</given-names></name><name><surname>Jacobs</surname><given-names>K</given-names></name><name><surname>Wheeler</surname><given-names>W</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Bergen</surname><given-names>AW</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Consonni</surname><given-names>D</given-names></name><name><surname>Pesatori</surname><given-names>AC</given-names></name><name><surname>Wacholder</surname><given-names>S</given-names></name><name><surname>Thun</surname><given-names>M</given-names></name><name><surname>Diver</surname><given-names>R</given-names></name><name><surname>Oken</surname><given-names>M</given-names></name><name><surname>Virtamo</surname><given-names>J</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Burdette</surname><given-names>L</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Laurie</surname><given-names>C</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Hung</surname><given-names>R</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tsao</surname><given-names>M-S</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Krokan</surname><given-names>H</given-names></name><name><surname>Vatten</surname><given-names>L</given-names></name><name><surname>Skorpen</surname><given-names>F</given-names></name><name><surname>Arnesen</surname><given-names>E</given-names></name><name><surname>Benhamou</surname><given-names>S</given-names></name><name><surname>Bouchard</surname><given-names>C</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Metsapalu</surname><given-names>A</given-names></name><name><surname>Vooder</surname><given-names>T</given-names></name><name><surname>Nelis</surname><given-names>M</given-names></name><name><surname>Välk</surname><given-names>K</given-names></name><name><surname>Field</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Goodman</surname><given-names>G</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Sauter</surname><given-names>W</given-names></name><name><surname>Rosenberger</surname><given-names>A</given-names></name><name><surname>Bickeböller</surname><given-names>H</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>Wichmann</surname><given-names>HE</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Houlston</surname><given-names>R</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names></name><name><surname>Savage</surname><given-names>SA</given-names></name><name><surname>Bertazzi</surname><given-names>PA</given-names></name><name><surname>Tucker</surname><given-names>MA</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A genome-wide association study of lung cancer identifies A region of chromosome 5p15 associated with risk for adenocarcinoma</article-title><source>American Journal of Human Genetics</source><volume>85</volume><fpage>679</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2009.09.012</pub-id><pub-id pub-id-type="pmid">19836008</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wedow</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Brazel</surname><given-names>DM</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Datta</surname><given-names>G</given-names></name><name><surname>Davila-Velderrain</surname><given-names>J</given-names></name><name><surname>McGuire</surname><given-names>D</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Zhan</surname><given-names>X</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Docherty</surname><given-names>AR</given-names></name><name><surname>Faul</surname><given-names>JD</given-names></name><name><surname>Foerster</surname><given-names>JR</given-names></name><name><surname>Fritsche</surname><given-names>LG</given-names></name><name><surname>Gabrielsen</surname><given-names>ME</given-names></name><name><surname>Gordon</surname><given-names>SD</given-names></name><name><surname>Haessler</surname><given-names>J</given-names></name><name><surname>Hottenga</surname><given-names>J-J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Jang</surname><given-names>S-K</given-names></name><name><surname>Jansen</surname><given-names>PR</given-names></name><name><surname>Ling</surname><given-names>Y</given-names></name><name><surname>Mägi</surname><given-names>R</given-names></name><name><surname>Matoba</surname><given-names>N</given-names></name><name><surname>McMahon</surname><given-names>G</given-names></name><name><surname>Mulas</surname><given-names>A</given-names></name><name><surname>Orrù</surname><given-names>V</given-names></name><name><surname>Palviainen</surname><given-names>T</given-names></name><name><surname>Pandit</surname><given-names>A</given-names></name><name><surname>Reginsson</surname><given-names>GW</given-names></name><name><surname>Skogholt</surname><given-names>AH</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Turman</surname><given-names>C</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Young</surname><given-names>H</given-names></name><name><surname>Young</surname><given-names>KA</given-names></name><name><surname>Zajac</surname><given-names>GJM</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Bjornsdottir</surname><given-names>G</given-names></name><name><surname>Boardman</surname><given-names>JD</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Davies</surname><given-names>GE</given-names></name><name><surname>Eaton</surname><given-names>CB</given-names></name><name><surname>Ehringer</surname><given-names>MA</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Fiorillo</surname><given-names>E</given-names></name><name><surname>Gillespie</surname><given-names>NA</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Haller</surname><given-names>T</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name><name><surname>Heath</surname><given-names>AC</given-names></name><name><surname>Hewitt</surname><given-names>JK</given-names></name><name><surname>Hickie</surname><given-names>IB</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Hopfer</surname><given-names>CJ</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Iacono</surname><given-names>WG</given-names></name><name><surname>Johnson</surname><given-names>EO</given-names></name><name><surname>Kamatani</surname><given-names>Y</given-names></name><name><surname>Kardia</surname><given-names>SLR</given-names></name><name><surname>Keller</surname><given-names>MC</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Krauter</surname><given-names>KS</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lind</surname><given-names>PA</given-names></name><name><surname>Loukola</surname><given-names>A</given-names></name><name><surname>Lutz</surname><given-names>SM</given-names></name><name><surname>Madden</surname><given-names>PAF</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>McGue</surname><given-names>M</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Medland</surname><given-names>SE</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Nielsen</surname><given-names>JB</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Polderman</surname><given-names>TJC</given-names></name><name><surname>Posthuma</surname><given-names>D</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Rimm</surname><given-names>E</given-names></name><name><surname>Rose</surname><given-names>RJ</given-names></name><name><surname>Runarsdottir</surname><given-names>V</given-names></name><name><surname>Stallings</surname><given-names>MC</given-names></name><name><surname>Stančáková</surname><given-names>A</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Thai</surname><given-names>KK</given-names></name><name><surname>Tindle</surname><given-names>HA</given-names></name><name><surname>Tyrfingsson</surname><given-names>T</given-names></name><name><surname>Wall</surname><given-names>TL</given-names></name><name><surname>Weir</surname><given-names>DR</given-names></name><name><surname>Weisner</surname><given-names>C</given-names></name><name><surname>Whitfield</surname><given-names>JB</given-names></name><name><surname>Winsvold</surname><given-names>BS</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zuccolo</surname><given-names>L</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Munafò</surname><given-names>MR</given-names></name><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Cornelis</surname><given-names>MC</given-names></name><name><surname>David</surname><given-names>SP</given-names></name><name><surname>Hinds</surname><given-names>DA</given-names></name><name><surname>Jorgenson</surname><given-names>E</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Stitzel</surname><given-names>JA</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>DJ</given-names></name><name><surname>Vrieze</surname><given-names>S</given-names></name><collab>23andMe Research Team</collab><collab>HUNT All-In Psychiatry</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use</article-title><source>Nature Genetics</source><volume>51</volume><fpage>237</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0307-5</pub-id><pub-id pub-id-type="pmid">30643251</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopes</surname><given-names>K</given-names></name><name><surname>Snijders</surname><given-names>GJL</given-names></name><name><surname>Humphrey</surname><given-names>J</given-names></name><name><surname>Allan</surname><given-names>A</given-names></name><name><surname>Sneeboer</surname><given-names>MAM</given-names></name><name><surname>Navarro</surname><given-names>E</given-names></name><name><surname>Schilder</surname><given-names>BM</given-names></name><name><surname>Vialle</surname><given-names>RA</given-names></name><name><surname>Parks</surname><given-names>M</given-names></name><name><surname>Missall</surname><given-names>R</given-names></name><name><surname>van Zuiden</surname><given-names>W</given-names></name><name><surname>Gigase</surname><given-names>FAJ</given-names></name><name><surname>Kübler</surname><given-names>R</given-names></name><name><surname>van Berlekom</surname><given-names>AB</given-names></name><name><surname>Hicks</surname><given-names>EM</given-names></name><name><surname>Bӧttcher</surname><given-names>C</given-names></name><name><surname>Priller</surname><given-names>J</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>de Witte</surname><given-names>LD</given-names></name><name><surname>Raj</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Genetic analysis of the human microglial transcriptome across brain regions, aging and disease pathologies</article-title><source>Nature Genetics</source><volume>54</volume><fpage>4</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00976-y</pub-id><pub-id pub-id-type="pmid">34992268</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McIntyre</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Polymerase iota - an odd sibling among Y family polymerases</article-title><source>DNA Repair</source><volume>86</volume><elocation-id>102753</elocation-id><pub-id pub-id-type="doi">10.1016/j.dnarep.2019.102753</pub-id><pub-id pub-id-type="pmid">31805501</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Gaborieau</surname><given-names>V</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Chabrier</surname><given-names>A</given-names></name><name><surname>Byrnes</surname><given-names>G</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Mukeria</surname><given-names>A</given-names></name><name><surname>Szeszenia-Dabrowska</surname><given-names>N</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Rudnai</surname><given-names>P</given-names></name><name><surname>Fabianova</surname><given-names>E</given-names></name><name><surname>Mates</surname><given-names>D</given-names></name><name><surname>Bencko</surname><given-names>V</given-names></name><name><surname>Foretova</surname><given-names>L</given-names></name><name><surname>Janout</surname><given-names>V</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Shepherd</surname><given-names>F</given-names></name><name><surname>Montpetit</surname><given-names>A</given-names></name><name><surname>Narod</surname><given-names>S</given-names></name><name><surname>Krokan</surname><given-names>HE</given-names></name><name><surname>Skorpen</surname><given-names>F</given-names></name><name><surname>Elvestad</surname><given-names>MB</given-names></name><name><surname>Vatten</surname><given-names>L</given-names></name><name><surname>Njølstad</surname><given-names>I</given-names></name><name><surname>Axelsson</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Goodman</surname><given-names>G</given-names></name><name><surname>Barnett</surname><given-names>M</given-names></name><name><surname>Loomis</surname><given-names>MM</given-names></name><name><surname>Lubiñski</surname><given-names>J</given-names></name><name><surname>Matyjasik</surname><given-names>J</given-names></name><name><surname>Lener</surname><given-names>M</given-names></name><name><surname>Oszutowska</surname><given-names>D</given-names></name><name><surname>Field</surname><given-names>J</given-names></name><name><surname>Liloglou</surname><given-names>T</given-names></name><name><surname>Xinarianos</surname><given-names>G</given-names></name><name><surname>Cassidy</surname><given-names>A</given-names></name><collab>EPIC Study</collab><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Clavel-Chapelon</surname><given-names>F</given-names></name><name><surname>Palli</surname><given-names>D</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Krogh</surname><given-names>V</given-names></name><name><surname>Panico</surname><given-names>S</given-names></name><name><surname>González</surname><given-names>CA</given-names></name><name><surname>Ramón Quirós</surname><given-names>J</given-names></name><name><surname>Martínez</surname><given-names>C</given-names></name><name><surname>Navarro</surname><given-names>C</given-names></name><name><surname>Ardanaz</surname><given-names>E</given-names></name><name><surname>Larrañaga</surname><given-names>N</given-names></name><name><surname>Kham</surname><given-names>KT</given-names></name><name><surname>Key</surname><given-names>T</given-names></name><name><surname>Bueno-de-Mesquita</surname><given-names>HB</given-names></name><name><surname>Peeters</surname><given-names>PH</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Linseisen</surname><given-names>J</given-names></name><name><surname>Boeing</surname><given-names>H</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Tjønneland</surname><given-names>A</given-names></name><name><surname>Kumle</surname><given-names>M</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Zelenika</surname><given-names>D</given-names></name><name><surname>Boland</surname><given-names>A</given-names></name><name><surname>Delepine</surname><given-names>M</given-names></name><name><surname>Foglio</surname><given-names>M</given-names></name><name><surname>Lechner</surname><given-names>D</given-names></name><name><surname>Matsuda</surname><given-names>F</given-names></name><name><surname>Blanche</surname><given-names>H</given-names></name><name><surname>Gut</surname><given-names>I</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><name><surname>Lathrop</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lung cancer susceptibility locus at 5p15.33</article-title><source>Nature Genetics</source><volume>40</volume><fpage>1404</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1038/ng.254</pub-id><pub-id pub-id-type="pmid">18978790</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKay</surname><given-names>JD</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Zong</surname><given-names>X</given-names></name><name><surname>Carreras-Torres</surname><given-names>R</given-names></name><name><surname>Christiani</surname><given-names>DC</given-names></name><name><surname>Caporaso</surname><given-names>NE</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Byun</surname><given-names>J</given-names></name><name><surname>Dunning</surname><given-names>A</given-names></name><name><surname>Pooley</surname><given-names>KA</given-names></name><name><surname>Qian</surname><given-names>DC</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Timofeeva</surname><given-names>MN</given-names></name><name><surname>Bojesen</surname><given-names>SE</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Bickeböller</surname><given-names>H</given-names></name><name><surname>Aldrich</surname><given-names>MC</given-names></name><name><surname>Bush</surname><given-names>WS</given-names></name><name><surname>Tardon</surname><given-names>A</given-names></name><name><surname>Rennert</surname><given-names>G</given-names></name><name><surname>Teare</surname><given-names>MD</given-names></name><name><surname>Field</surname><given-names>JK</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Lazarus</surname><given-names>P</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Andrew</surname><given-names>AS</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>Y-C</given-names></name><name><surname>Yuan</surname><given-names>J-M</given-names></name><name><surname>Bertazzi</surname><given-names>PA</given-names></name><name><surname>Pesatori</surname><given-names>AC</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Diao</surname><given-names>N</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Brhane</surname><given-names>Y</given-names></name><name><surname>Leighl</surname><given-names>N</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Mellemgaard</surname><given-names>A</given-names></name><name><surname>Saliba</surname><given-names>W</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Wilkens</surname><given-names>LR</given-names></name><name><surname>Fernandez-Somoano</surname><given-names>A</given-names></name><name><surname>Fernandez-Tardon</surname><given-names>G</given-names></name><name><surname>van der Heijden</surname><given-names>HFM</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Davies</surname><given-names>MPA</given-names></name><name><surname>Marcus</surname><given-names>MW</given-names></name><name><surname>Brunnström</surname><given-names>H</given-names></name><name><surname>Manjer</surname><given-names>J</given-names></name><name><surname>Melander</surname><given-names>O</given-names></name><name><surname>Muller</surname><given-names>DC</given-names></name><name><surname>Overvad</surname><given-names>K</given-names></name><name><surname>Trichopoulou</surname><given-names>A</given-names></name><name><surname>Tumino</surname><given-names>R</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Barnett</surname><given-names>MP</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Cox</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>F</given-names></name><name><surname>Woll</surname><given-names>P</given-names></name><name><surname>Brüske</surname><given-names>I</given-names></name><name><surname>Wichmann</surname><given-names>H-E</given-names></name><name><surname>Manz</surname><given-names>J</given-names></name><name><surname>Muley</surname><given-names>TR</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Rosenberger</surname><given-names>A</given-names></name><name><surname>Grankvist</surname><given-names>K</given-names></name><name><surname>Johansson</surname><given-names>M</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Tsao</surname><given-names>M-S</given-names></name><name><surname>Arnold</surname><given-names>SM</given-names></name><name><surname>Haura</surname><given-names>EB</given-names></name><name><surname>Bolca</surname><given-names>C</given-names></name><name><surname>Holcatova</surname><given-names>I</given-names></name><name><surname>Janout</surname><given-names>V</given-names></name><name><surname>Kontic</surname><given-names>M</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Mukeria</surname><given-names>A</given-names></name><name><surname>Ognjanovic</surname><given-names>S</given-names></name><name><surname>Orlowski</surname><given-names>TM</given-names></name><name><surname>Scelo</surname><given-names>G</given-names></name><name><surname>Swiatkowska</surname><given-names>B</given-names></name><name><surname>Zaridze</surname><given-names>D</given-names></name><name><surname>Bakke</surname><given-names>P</given-names></name><name><surname>Skaug</surname><given-names>V</given-names></name><name><surname>Zienolddiny</surname><given-names>S</given-names></name><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Butler</surname><given-names>LM</given-names></name><name><surname>Koh</surname><given-names>W-P</given-names></name><name><surname>Gao</surname><given-names>Y-T</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>McLaughlin</surname><given-names>J</given-names></name><name><surname>Stevens</surname><given-names>VL</given-names></name><name><surname>Joubert</surname><given-names>P</given-names></name><name><surname>Lamontagne</surname><given-names>M</given-names></name><name><surname>Nickle</surname><given-names>DC</given-names></name><name><surname>Obeidat</surname><given-names>M</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>L</given-names></name><name><surname>Kachuri</surname><given-names>L</given-names></name><name><surname>Artigas</surname><given-names>MS</given-names></name><name><surname>Tobin</surname><given-names>MD</given-names></name><name><surname>Wain</surname><given-names>LV</given-names></name><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Reginsson</surname><given-names>GW</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Hancock</surname><given-names>DB</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Gaddis</surname><given-names>NC</given-names></name><name><surname>Lutz</surname><given-names>SM</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Johnson</surname><given-names>EO</given-names></name><name><surname>Kamal</surname><given-names>A</given-names></name><name><surname>Pikielny</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Lindströem</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Tyndale</surname><given-names>RF</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Beesley</surname><given-names>J</given-names></name><name><surname>Bossé</surname><given-names>Y</given-names></name><name><surname>Chanock</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><collab>SpiroMeta Consortium</collab></person-group><year iso-8601-date="2017">2017</year><article-title>Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes</article-title><source>Nature Genetics</source><volume>49</volume><fpage>1126</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1038/ng.3892</pub-id><pub-id pub-id-type="pmid">28604730</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montpetit</surname><given-names>AJ</given-names></name><name><surname>Alhareeri</surname><given-names>AA</given-names></name><name><surname>Montpetit</surname><given-names>M</given-names></name><name><surname>Starkweather</surname><given-names>AR</given-names></name><name><surname>Elmore</surname><given-names>LW</given-names></name><name><surname>Filler</surname><given-names>K</given-names></name><name><surname>Mohanraj</surname><given-names>L</given-names></name><name><surname>Burton</surname><given-names>CW</given-names></name><name><surname>Menzies</surname><given-names>VS</given-names></name><name><surname>Lyon</surname><given-names>DE</given-names></name><name><surname>Jackson-Cook</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Telomere length: a review of methods for measurement</article-title><source>Nursing Research</source><volume>63</volume><fpage>289</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1097/NNR.0000000000000037</pub-id><pub-id pub-id-type="pmid">24977726</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Penha</surname><given-names>RCC</given-names></name></person-group><year iso-8601-date="2023">2023a</year><data-title>Telomere_Length_Code</data-title><version designator="swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2">swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:f173a1fa2257be749737ff70cb6ab1a99d775a35;origin=https://github.com/ricardocortezcardoso/Telomere_Length_Code;visit=swh:1:snp:f384d579f907421d4a850fb22aa5ec80d4d00c9c;anchor=swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2">https://archive.softwareheritage.org/swh:1:dir:f173a1fa2257be749737ff70cb6ab1a99d775a35;origin=https://github.com/ricardocortezcardoso/Telomere_Length_Code;visit=swh:1:snp:f384d579f907421d4a850fb22aa5ec80d4d00c9c;anchor=swh:1:rev:f365df300919c46bb99a96b4040d90576fc878e2</ext-link></element-citation></ref><ref id="bib37"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Penha</surname><given-names>RCC</given-names></name></person-group><year iso-8601-date="2023">2023b</year><data-title>Gassocplot</data-title><version designator="swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b">swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:2776666d17e41041280a9474bd480c42d7717aec;origin=https://github.com/jrs95/gassocplot;visit=swh:1:snp:fa85aef5febdc1b7f8556fa537013757f6c73915;anchor=swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b">https://archive.softwareheritage.org/swh:1:dir:2776666d17e41041280a9474bd480c42d7717aec;origin=https://github.com/jrs95/gassocplot;visit=swh:1:snp:fa85aef5febdc1b7f8556fa537013757f6c73915;anchor=swh:1:rev:ae6a59dff2e43d39eead3d483af1d50f151c3d5b</ext-link></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pulit</surname><given-names>SL</given-names></name><name><surname>Stoneman</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Wood</surname><given-names>AR</given-names></name><name><surname>Glastonbury</surname><given-names>CA</given-names></name><name><surname>Tyrrell</surname><given-names>J</given-names></name><name><surname>Yengo</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>T</given-names></name><name><surname>Marouli</surname><given-names>E</given-names></name><name><surname>Ji</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Beaumont</surname><given-names>R</given-names></name><name><surname>Croteau-Chonka</surname><given-names>DC</given-names></name><name><surname>Winkler</surname><given-names>TW</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Visscher</surname><given-names>PM</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Yaghootkar</surname><given-names>H</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><collab>GIANT Consortium</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of european ancestry</article-title><source>Human Molecular Genetics</source><volume>28</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddy327</pub-id><pub-id pub-id-type="pmid">30239722</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rafnar</surname><given-names>T</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Stacey</surname><given-names>SN</given-names></name><name><surname>Geller</surname><given-names>F</given-names></name><name><surname>Gudmundsson</surname><given-names>J</given-names></name><name><surname>Sigurdsson</surname><given-names>A</given-names></name><name><surname>Jakobsdottir</surname><given-names>M</given-names></name><name><surname>Helgadottir</surname><given-names>H</given-names></name><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Aben</surname><given-names>KKH</given-names></name><name><surname>Blöndal</surname><given-names>T</given-names></name><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Kristjansson</surname><given-names>K</given-names></name><name><surname>Thorisdottir</surname><given-names>K</given-names></name><name><surname>Ragnarsson</surname><given-names>R</given-names></name><name><surname>Sigurgeirsson</surname><given-names>B</given-names></name><name><surname>Skuladottir</surname><given-names>H</given-names></name><name><surname>Gudbjartsson</surname><given-names>T</given-names></name><name><surname>Isaksson</surname><given-names>HJ</given-names></name><name><surname>Einarsson</surname><given-names>GV</given-names></name><name><surname>Benediktsdottir</surname><given-names>KR</given-names></name><name><surname>Agnarsson</surname><given-names>BA</given-names></name><name><surname>Olafsson</surname><given-names>K</given-names></name><name><surname>Salvarsdottir</surname><given-names>A</given-names></name><name><surname>Bjarnason</surname><given-names>H</given-names></name><name><surname>Asgeirsdottir</surname><given-names>M</given-names></name><name><surname>Kristinsson</surname><given-names>KT</given-names></name><name><surname>Matthiasdottir</surname><given-names>S</given-names></name><name><surname>Sveinsdottir</surname><given-names>SG</given-names></name><name><surname>Polidoro</surname><given-names>S</given-names></name><name><surname>Höiom</surname><given-names>V</given-names></name><name><surname>Botella-Estrada</surname><given-names>R</given-names></name><name><surname>Hemminki</surname><given-names>K</given-names></name><name><surname>Rudnai</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Campagna</surname><given-names>M</given-names></name><name><surname>Kellen</surname><given-names>E</given-names></name><name><surname>Zeegers</surname><given-names>MP</given-names></name><name><surname>de Verdier</surname><given-names>P</given-names></name><name><surname>Ferrer</surname><given-names>A</given-names></name><name><surname>Isla</surname><given-names>D</given-names></name><name><surname>Vidal</surname><given-names>MJ</given-names></name><name><surname>Andres</surname><given-names>R</given-names></name><name><surname>Saez</surname><given-names>B</given-names></name><name><surname>Juberias</surname><given-names>P</given-names></name><name><surname>Banzo</surname><given-names>J</given-names></name><name><surname>Navarrete</surname><given-names>S</given-names></name><name><surname>Tres</surname><given-names>A</given-names></name><name><surname>Kan</surname><given-names>D</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Gurzau</surname><given-names>E</given-names></name><name><surname>Koppova</surname><given-names>K</given-names></name><name><surname>de Vegt</surname><given-names>F</given-names></name><name><surname>Schalken</surname><given-names>JA</given-names></name><name><surname>van der Heijden</surname><given-names>HFM</given-names></name><name><surname>Smit</surname><given-names>HJ</given-names></name><name><surname>Termeer</surname><given-names>RA</given-names></name><name><surname>Oosterwijk</surname><given-names>E</given-names></name><name><surname>van Hooij</surname><given-names>O</given-names></name><name><surname>Nagore</surname><given-names>E</given-names></name><name><surname>Porru</surname><given-names>S</given-names></name><name><surname>Steineck</surname><given-names>G</given-names></name><name><surname>Hansson</surname><given-names>J</given-names></name><name><surname>Buntinx</surname><given-names>F</given-names></name><name><surname>Catalona</surname><given-names>WJ</given-names></name><name><surname>Matullo</surname><given-names>G</given-names></name><name><surname>Vineis</surname><given-names>P</given-names></name><name><surname>Kiltie</surname><given-names>AE</given-names></name><name><surname>Mayordomo</surname><given-names>JI</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Kiemeney</surname><given-names>LA</given-names></name><name><surname>Frigge</surname><given-names>ML</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Saemundsson</surname><given-names>H</given-names></name><name><surname>Barkardottir</surname><given-names>RB</given-names></name><name><surname>Jonsson</surname><given-names>E</given-names></name><name><surname>Jonsson</surname><given-names>S</given-names></name><name><surname>Olafsson</surname><given-names>JH</given-names></name><name><surname>Gulcher</surname><given-names>JR</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sequence variants at the TERT-CLPTM1L locus associate with many cancer types</article-title><source>Nature Genetics</source><volume>41</volume><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1038/ng.296</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Risso</surname><given-names>D</given-names></name><name><surname>Schwartz</surname><given-names>K</given-names></name><name><surname>Sherlock</surname><given-names>G</given-names></name><name><surname>Dudoit</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gc-Content normalization for RNA-Seq data</article-title><source>BMC Bioinformatics</source><volume>12</volume><elocation-id>480</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-12-480</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sainz de Aja</surname><given-names>J</given-names></name><name><surname>Dost</surname><given-names>AFM</given-names></name><name><surname>Kim</surname><given-names>CF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Alveolar progenitor cells and the origin of lung cancer</article-title><source>Journal of Internal Medicine</source><volume>289</volume><fpage>629</fpage><lpage>635</lpage><pub-id pub-id-type="doi">10.1111/joim.13201</pub-id><pub-id pub-id-type="pmid">33340175</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanchez-Espiridion</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>JY</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>DW</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in caucasians</article-title><source>Cancer Research</source><volume>74</volume><fpage>2476</fpage><lpage>2486</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2968</pub-id><pub-id pub-id-type="pmid">24618342</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>E</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Windmeijer</surname><given-names>F</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings</article-title><source>International Journal of Epidemiology</source><volume>48</volume><fpage>713</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1093/ije/dyy262</pub-id><pub-id pub-id-type="pmid">30535378</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanderson</surname><given-names>E</given-names></name><name><surname>Glymour</surname><given-names>MM</given-names></name><name><surname>Holmes</surname><given-names>MV</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Munafò</surname><given-names>MR</given-names></name><name><surname>Palmer</surname><given-names>T</given-names></name><name><surname>Schooling</surname><given-names>CM</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mendelian randomization</article-title><source>Nature Reviews Methods Primers</source><volume>2</volume><elocation-id>00092-5</elocation-id><pub-id pub-id-type="doi">10.1038/s43586-021-00092-5</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>GRB</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Jang</surname><given-names>S-K</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Khunsriraksakul</surname><given-names>C</given-names></name><name><surname>Otto</surname><given-names>JM</given-names></name><name><surname>Addison</surname><given-names>C</given-names></name><name><surname>Akiyama</surname><given-names>M</given-names></name><name><surname>Albert</surname><given-names>CM</given-names></name><name><surname>Aliev</surname><given-names>F</given-names></name><name><surname>Alonso</surname><given-names>A</given-names></name><name><surname>Arnett</surname><given-names>DK</given-names></name><name><surname>Ashley-Koch</surname><given-names>AE</given-names></name><name><surname>Ashrani</surname><given-names>AA</given-names></name><name><surname>Barnes</surname><given-names>KC</given-names></name><name><surname>Barr</surname><given-names>RG</given-names></name><name><surname>Bartz</surname><given-names>TM</given-names></name><name><surname>Becker</surname><given-names>DM</given-names></name><name><surname>Bielak</surname><given-names>LF</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Bis</surname><given-names>JC</given-names></name><name><surname>Bjornsdottir</surname><given-names>G</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Bleecker</surname><given-names>ER</given-names></name><name><surname>Boardman</surname><given-names>JD</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Boorgula</surname><given-names>MP</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name><name><surname>Brody</surname><given-names>JA</given-names></name><name><surname>Cade</surname><given-names>BE</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Chavan</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y-DI</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>I</given-names></name><name><surname>Cho</surname><given-names>MH</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>JW</given-names></name><name><surname>Cornelis</surname><given-names>MC</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>Curran</surname><given-names>JE</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Dick</surname><given-names>DM</given-names></name><name><surname>Docherty</surname><given-names>AR</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>Eaton</surname><given-names>CB</given-names></name><name><surname>Ehringer</surname><given-names>MA</given-names></name><name><surname>Esko</surname><given-names>T</given-names></name><name><surname>Faul</surname><given-names>JD</given-names></name><name><surname>Fernandes Silva</surname><given-names>L</given-names></name><name><surname>Fiorillo</surname><given-names>E</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Freedman</surname><given-names>BI</given-names></name><name><surname>Gabrielsen</surname><given-names>ME</given-names></name><name><surname>Garrett</surname><given-names>ME</given-names></name><name><surname>Gharib</surname><given-names>SA</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Gillespie</surname><given-names>N</given-names></name><name><surname>Glahn</surname><given-names>DC</given-names></name><name><surname>Gordon</surname><given-names>SD</given-names></name><name><surname>Gu</surname><given-names>CC</given-names></name><name><surname>Gu</surname><given-names>D</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Haessler</surname><given-names>J</given-names></name><name><surname>Hall</surname><given-names>ME</given-names></name><name><surname>Haller</surname><given-names>T</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Herd</surname><given-names>P</given-names></name><name><surname>Hewitt</surname><given-names>JK</given-names></name><name><surname>Hickie</surname><given-names>I</given-names></name><name><surname>Hidalgo</surname><given-names>B</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><name><surname>Hopfer</surname><given-names>C</given-names></name><name><surname>Hottenga</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Hung</surname><given-names>Y-J</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>S-J</given-names></name><name><surname>Hwu</surname><given-names>C-M</given-names></name><name><surname>Iacono</surname><given-names>W</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><name><surname>Jee</surname><given-names>YH</given-names></name><name><surname>Johnson</surname><given-names>EO</given-names></name><name><surname>Joo</surname><given-names>YY</given-names></name><name><surname>Jorgenson</surname><given-names>E</given-names></name><name><surname>Justice</surname><given-names>AE</given-names></name><name><surname>Kamatani</surname><given-names>Y</given-names></name><name><surname>Kaplan</surname><given-names>RC</given-names></name><name><surname>Kaprio</surname><given-names>J</given-names></name><name><surname>Kardia</surname><given-names>SLR</given-names></name><name><surname>Keller</surname><given-names>MC</given-names></name><name><surname>Kelly</surname><given-names>TN</given-names></name><name><surname>Kooperberg</surname><given-names>C</given-names></name><name><surname>Korhonen</surname><given-names>T</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Krauter</surname><given-names>K</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lasky-Su</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>W-J</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name><name><surname>Lind</surname><given-names>PA</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Lloyd-Jones</surname><given-names>DM</given-names></name><name><surname>Lutz</surname><given-names>SM</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Mägi</surname><given-names>R</given-names></name><name><surname>Manichaikul</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Mathur</surname><given-names>R</given-names></name><name><surname>Matoba</surname><given-names>N</given-names></name><name><surname>McArdle</surname><given-names>PF</given-names></name><name><surname>McGue</surname><given-names>M</given-names></name><name><surname>McQueen</surname><given-names>MB</given-names></name><name><surname>Medland</surname><given-names>SE</given-names></name><name><surname>Metspalu</surname><given-names>A</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Millwood</surname><given-names>IY</given-names></name><name><surname>Mitchell</surname><given-names>BD</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Moll</surname><given-names>M</given-names></name><name><surname>Montasser</surname><given-names>ME</given-names></name><name><surname>Morrison</surname><given-names>AC</given-names></name><name><surname>Mulas</surname><given-names>A</given-names></name><name><surname>Nielsen</surname><given-names>JB</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>Oelsner</surname><given-names>EC</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Orrù</surname><given-names>V</given-names></name><name><surname>Palmer</surname><given-names>ND</given-names></name><name><surname>Palviainen</surname><given-names>T</given-names></name><name><surname>Pandit</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>SL</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Peyser</surname><given-names>PA</given-names></name><name><surname>Polderman</surname><given-names>TJC</given-names></name><name><surname>Rafaels</surname><given-names>N</given-names></name><name><surname>Redline</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>RM</given-names></name><name><surname>Reiner</surname><given-names>AP</given-names></name><name><surname>Rice</surname><given-names>JP</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Richmond</surname><given-names>NE</given-names></name><name><surname>Roan</surname><given-names>C</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Rueschman</surname><given-names>MN</given-names></name><name><surname>Runarsdottir</surname><given-names>V</given-names></name><name><surname>Saccone</surname><given-names>NL</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name><name><surname>Shadyab</surname><given-names>AH</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Shringarpure</surname><given-names>SS</given-names></name><name><surname>Sicinski</surname><given-names>K</given-names></name><name><surname>Skogholt</surname><given-names>AH</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>NL</given-names></name><name><surname>Sotoodehnia</surname><given-names>N</given-names></name><name><surname>Stallings</surname><given-names>MC</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Stitzel</surname><given-names>JA</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Syed</surname><given-names>M</given-names></name><name><surname>Tal-Singer</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>AE</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Telen</surname><given-names>MJ</given-names></name><name><surname>Thai</surname><given-names>KK</given-names></name><name><surname>Tiwari</surname><given-names>H</given-names></name><name><surname>Turman</surname><given-names>C</given-names></name><name><surname>Tyrfingsson</surname><given-names>T</given-names></name><name><surname>Wall</surname><given-names>TL</given-names></name><name><surname>Walters</surname><given-names>RG</given-names></name><name><surname>Weir</surname><given-names>DR</given-names></name><name><surname>Weiss</surname><given-names>ST</given-names></name><name><surname>White</surname><given-names>WB</given-names></name><name><surname>Whitfield</surname><given-names>JB</given-names></name><name><surname>Wiggins</surname><given-names>KL</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Willer</surname><given-names>CJ</given-names></name><name><surname>Winsvold</surname><given-names>BS</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Yanek</surname><given-names>LR</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>KL</given-names></name><name><surname>Young</surname><given-names>KA</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Zöllner</surname><given-names>S</given-names></name><name><surname>Zuccolo</surname><given-names>L</given-names></name><name><surname>Batini</surname><given-names>C</given-names></name><name><surname>Bergen</surname><given-names>AW</given-names></name><name><surname>Bierut</surname><given-names>LJ</given-names></name><name><surname>David</surname><given-names>SP</given-names></name><name><surname>Gagliano Taliun</surname><given-names>SA</given-names></name><name><surname>Hancock</surname><given-names>DB</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Munafò</surname><given-names>MR</given-names></name><name><surname>Thorgeirsson</surname><given-names>TE</given-names></name><name><surname>Liu</surname><given-names>DJ</given-names></name><name><surname>Vrieze</surname><given-names>S</given-names></name><collab>23andMe Research Team</collab><collab>Biobank Japan Project</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Genetic diversity fuels gene discovery for tobacco and alcohol use</article-title><source>Nature</source><volume>612</volume><fpage>720</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05477-4</pub-id><pub-id pub-id-type="pmid">36477530</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>PNAS</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsson</surname><given-names>V</given-names></name><name><surname>Gibbs</surname><given-names>DL</given-names></name><name><surname>Brown</surname><given-names>SD</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Bortone</surname><given-names>DS</given-names></name><name><surname>Ou Yang</surname><given-names>T-H</given-names></name><name><surname>Porta-Pardo</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Plaisier</surname><given-names>CL</given-names></name><name><surname>Eddy</surname><given-names>JA</given-names></name><name><surname>Ziv</surname><given-names>E</given-names></name><name><surname>Culhane</surname><given-names>AC</given-names></name><name><surname>Paull</surname><given-names>EO</given-names></name><name><surname>Sivakumar</surname><given-names>IKA</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Malhotra</surname><given-names>R</given-names></name><name><surname>Farshidfar</surname><given-names>F</given-names></name><name><surname>Colaprico</surname><given-names>A</given-names></name><name><surname>Parker</surname><given-names>JS</given-names></name><name><surname>Mose</surname><given-names>LE</given-names></name><name><surname>Vo</surname><given-names>NS</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rader</surname><given-names>J</given-names></name><name><surname>Dhankani</surname><given-names>V</given-names></name><name><surname>Reynolds</surname><given-names>SM</given-names></name><name><surname>Bowlby</surname><given-names>R</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Anastassiou</surname><given-names>D</given-names></name><name><surname>Bedognetti</surname><given-names>D</given-names></name><name><surname>Mokrab</surname><given-names>Y</given-names></name><name><surname>Newman</surname><given-names>AM</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Krasnitz</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Malta</surname><given-names>TM</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Pedamallu</surname><given-names>CS</given-names></name><name><surname>Bullman</surname><given-names>S</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Lamb</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Guinney</surname><given-names>J</given-names></name><name><surname>Saltz</surname><given-names>J</given-names></name><name><surname>Holt</surname><given-names>RA</given-names></name><name><surname>Rabkin</surname><given-names>CS</given-names></name><name><surname>Lazar</surname><given-names>AJ</given-names></name><name><surname>Serody</surname><given-names>JS</given-names></name><name><surname>Demicco</surname><given-names>EG</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name><name><surname>Vincent</surname><given-names>BG</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>The immune landscape of cancer</article-title><source>Immunity</source><volume>48</volume><fpage>812</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.023</pub-id><pub-id pub-id-type="pmid">29628290</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses</article-title><source>PLOS Genetics</source><volume>16</volume><elocation-id>e1008720</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1008720</pub-id><pub-id pub-id-type="pmid">32310995</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A more accurate method for colocalisation analysis allowing for multiple causal variants</article-title><source>PLOS Genetics</source><volume>17</volume><elocation-id>e1009440</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1009440</pub-id><pub-id pub-id-type="pmid">34587156</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Broderick</surname><given-names>P</given-names></name><name><surname>Webb</surname><given-names>E</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Vijayakrishnan</surname><given-names>J</given-names></name><name><surname>Matakidou</surname><given-names>A</given-names></name><name><surname>Qureshi</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Spitz</surname><given-names>MR</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Common 5p15.33 and 6p21.33 variants influence lung cancer risk</article-title><source>Nature Genetics</source><volume>40</volume><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/ng.273</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1972">1972</year><article-title>Origin of concatemeric T7 DNA</article-title><source>Nature</source><volume>239</volume><fpage>197</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1038/newbio239197a0</pub-id><pub-id pub-id-type="pmid">4507727</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yavorska</surname><given-names>OO</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data</article-title><source>International Journal of Epidemiology</source><volume>46</volume><fpage>1734</fpage><lpage>1739</lpage><pub-id pub-id-type="doi">10.1093/ije/dyx034</pub-id><pub-id pub-id-type="pmid">28398548</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Doherty</surname><given-names>JA</given-names></name><name><surname>Burgess</surname><given-names>S</given-names></name><name><surname>Hung</surname><given-names>RJ</given-names></name><name><surname>Lindström</surname><given-names>S</given-names></name><name><surname>Kraft</surname><given-names>P</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Sellers</surname><given-names>TA</given-names></name><name><surname>Monteiro</surname><given-names>ANA</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name><name><surname>Bickeböller</surname><given-names>H</given-names></name><name><surname>Risch</surname><given-names>A</given-names></name><name><surname>Brennan</surname><given-names>P</given-names></name><name><surname>Mckay</surname><given-names>JD</given-names></name><name><surname>Houlston</surname><given-names>RS</given-names></name><name><surname>Landi</surname><given-names>MT</given-names></name><name><surname>Timofeeva</surname><given-names>MN</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Heinrich</surname><given-names>J</given-names></name><name><surname>Kote-Jarai</surname><given-names>Z</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Muir</surname><given-names>K</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Grönberg</surname><given-names>H</given-names></name><name><surname>Berndt</surname><given-names>SI</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Schumacher</surname><given-names>F</given-names></name><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Henderson</surname><given-names>BE</given-names></name><name><surname>Amin Al Olama</surname><given-names>A</given-names></name><name><surname>Andrulis</surname><given-names>IL</given-names></name><name><surname>Hopper</surname><given-names>JL</given-names></name><name><surname>Chang-Claude</surname><given-names>J</given-names></name><name><surname>John</surname><given-names>EM</given-names></name><name><surname>Malone</surname><given-names>KE</given-names></name><name><surname>Gammon</surname><given-names>MD</given-names></name><name><surname>Ursin</surname><given-names>G</given-names></name><name><surname>Whittemore</surname><given-names>AS</given-names></name><name><surname>Hunter</surname><given-names>DJ</given-names></name><name><surname>Gruber</surname><given-names>SB</given-names></name><name><surname>Knight</surname><given-names>JA</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name><name><surname>Newcomb</surname><given-names>PA</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Chan</surname><given-names>AT</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Woods</surname><given-names>MO</given-names></name><name><surname>Ahsan</surname><given-names>H</given-names></name><name><surname>Pierce</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study</article-title><source>Human Molecular Genetics</source><volume>24</volume><fpage>5356</fpage><lpage>5366</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddv252</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Xie</surname><given-names>SH</given-names></name><name><surname>Zhong</surname><given-names>LX</given-names></name><name><surname>Cai</surname><given-names>YY</given-names></name><name><surname>Li</surname><given-names>XN</given-names></name><name><surname>Liang</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>QS</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The association of telomere length in peripheral blood cells with cancer risk: a systematic review and meta-analysis of prospective studies</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>26</volume><fpage>1381</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0968</pub-id><pub-id pub-id-type="pmid">28619828</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><sec sec-type="appendix" id="s8"><title>Additional methods: Datasets</title><sec sec-type="appendix" id="s8-1"><title>UK Biobank</title><p>The UK Biobank (UKBB) is a large cohort with more than 500,000 individuals from the United Kingdom who were recruited between 2006 and 2010, as previously described (<xref ref-type="bibr" rid="bib5">Bycroft et al., 2018</xref>). At the time of recruitment, individuals provided electronic signed consent, answered questions regarding socio-demographic, lifestyle, health-related factors, and physical measures. The genetic data were obtained using the UK BiLEVE and the UKBB Axiom arrays. UKBB has ethical approval from the National Information Governance Board for Health and Social Care and the North-West Multicentre Research Ethics Committee (Ref: 11/NW/0382).</p><p>The latest genome-wide association study (GWAS) summary statistics of leukocyte telomere length (LTL; <ext-link ext-link-type="uri" xlink:href="https://figshare.com/s/caa99dc0f76d62990195">https://figshare.com/s/caa99dc0f76d62990195</ext-link>) were performed on 464,716 UKBB participants of European ancestry with 19.4 million imputed variants ( minor allele frequency≥ 1% and imputation quality score ≥0.3), adjusting by age, sex, array, and the first 10 principal components. LTL was measured from UKBB baseline samples, and values were log-transformed and Z-standardised.</p><p>The forced expiratory volume in 1 s (FEV<sub>1</sub>) and forced vital capacity (FVC) GWAS summary statistics were conducted on 372,750 and 370,638 individuals of European genetic ancestry, respectively, who had spirometry data and sample passed quality control of genetic data (Hardy–Weinberg equilibrium at p&gt;1 × 10<sup>−5</sup>, MAF &gt;0.5%, and imputation quality score ≥0.3). Linear regression models were applied to standardised Z-scores for FEV<sub>1</sub> and FVC, adjusting by age, sex, genotyping array, and 15 principal components. These GWAS summary statistics are available by the corresponding authors of the original article upon reasonable request (see <xref ref-type="bibr" rid="bib27">Kachuri et al., 2020</xref>).</p></sec><sec sec-type="appendix" id="s8-2"><title>International lung cancer consortium</title><p>The International Lung Cancer Consortium (ILCCO) is an international group of lung cancer researchers for sharing comparable data from ongoing lung cancer case-control and cohort studies. The lung cancer GWAS summary statistics used in the current work is derived from a collaborative effort between Transdisciplinary Research of Cancer in Lung of the ILCCO (TRICL-ILCCO) and the Lung Cancer Cohort Consortium (LC3). All participants in these studies signed an informed consent, approved by the local internal review board or ethics committee.</p><p>The lung cancer GWAS summary statistic (29,266 cases and 56,450 controls of European descent; <xref ref-type="bibr" rid="bib34">McKay et al., 2017</xref>) is meta-analysis of the combined imputed genotypes from OncoArray series (14,803 cases and 12,262 controls) and previous lung cancer GWAS (IARC, MDACC, SLRI, ICR, Harvard, NCI, Germany, and deCODE studies; 44,188 controls and 14,436 cases). The meta-analysis only considered imputed variants with MAF &gt;1%, imputation quality score ≥0.3, and with little evidence for heterogeneity in effect between the studies (Cochran’s Q statistic: p&gt;0.05), adjusting by sex, age, and principal components. Additionally, analyses were conducted by lung cancer histological subtype (adenocarcinoma [11,273 cases and 55,483 controls], squamous cell carcinoma [7426 cases and 55,627 controls], and small-cell carcinoma [2664 cases and 21,444 controls]). Of note, histological subtype information was not available for all studies.</p></sec><sec sec-type="appendix" id="s8-3"><title>The GWAS and Sequencing Consortium of Alcohol and Nicotine use consortium</title><p>The GWAS and Sequencing Consortium of Alcohol and Nicotine use dataset is derived from an international genetic association meta-analysis consortium for tobacco smoking and alcohol consumption traits across 30 studies and up to 1.2 million individuals (<xref ref-type="bibr" rid="bib30">Liu et al., 2019</xref>). For the GWAS summary statistics used in the current study, UKBB participants were excluded from the meta-analysis, and only genetic variants present in more than 19 studies, MAF &gt;1%, and imputation quality score &gt;0.3 were considered. The smoking traits were defined as follow: cigarettes per day (CPD; N=337,334; continuous variable defined as average number of cigarettes smoked per day, either as a current smoker or former smoker), smoking initiation (SmkInit; N=1,232,091; categorical variable defined as ever smokers versus never smokers), smoking cessation (SmkCes; N=547,219; categorical variable defined as current smokers versus former smokers), and age of initiation (AgeSmk; N=341,427; continuous variable defined as the age at which an individual first became a regular smoker). Age, sex, and genetic principal components were used as covariates in all analyses. GWAS summary statistics were downloaded from <ext-link ext-link-type="uri" xlink:href="https://conservancy.umn.edu/handle/11299/201564">https://conservancy.umn.edu/handle/11299/201564</ext-link>.</p><p>The Genotype-Tissue Expression (GTEx) project data is a project that aims to investigate the effects of genetic variants in transcriptome and their impact on regulatory mechanisms of a traits and diseases (<xref ref-type="bibr" rid="bib18">GTEx Consortium, 2020</xref>). The GTEx data contain 15,201 RNA-sequencing samples from 49 tissues of 838 postmortem donors. For the current study, we accessed version 8 of the GTEx program to obtain the effect estimates and risk alleles of eQTL genetic variants (in normal lung tissue) around the queried SNPs for the multi-trait colocalisation analyses.</p></sec></sec><sec sec-type="appendix" id="s9"><title>The Cancer Genome Atlas</title><p>The Cancer Genome Atlas (TCGA) is currently the biggest resource of cancer genomics, with more than 20,000 primary cancer and matched normal samples molecularly characterised across 33 cancer types with available demographic and clinical data.</p><p>For the current study, the access for the germline data of TCGA dataset was obtained via TCGA project #2731 via dbGAP (phs000178.v11.p8). Genotyping and imputation from TCGA data were performed in-house and described elsewhere (<xref ref-type="bibr" rid="bib16">Gabriel et al., 2022</xref>). Briefly, germline variants with low genotyping call rate (&lt;97%), MAF &lt;1%, strong deviation (p-value&lt;10<sup>–8</sup>) from the Hardy–Weinberg equilibrium, and allele frequency differing more than 20% from 1000 Genomes (1000 G) within European ancestry group were removed. Phasing was performed using Eagle (v2.4.1; <xref ref-type="bibr" rid="bib15">Gabriel and Lipinski, 2021</xref>) with the 1000 genomes phase 3 reference panel, and Minimac4 (v1.0.1; <xref ref-type="bibr" rid="bib15">Gabriel and Lipinski, 2021</xref>) was used to perform the imputation (window size of 500 kb; <xref ref-type="bibr" rid="bib9">Das et al., 2016</xref>). Samples with discrepancies between genetic inferred and self-reported sex as well as with high inter-sample relatedness (PI_HAT &gt;0.185%) were removed.</p><p>Of the 480 lung adenocarcinoma cases with genotype data, 364 cases had available tumour RNA-sequencing data (more details in Data availability section). We excluded 20 cases due to missing information for smoking status (ever smokers versus never smokers) from the downstream analyses. After summarising the normalised log-transformed read counts for all genes in two dimensions, one sample was removed due to extreme gene expression profile in comparison with all the lung adenocarcinoma tumours. Thus, 343 lung adenocarcinoma tumour samples were selected for the principal component analysis and association with LTL polygenic risk score (PRS), molecular, clinic, and demographic variables of TCGA dataset.</p></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83118.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Banovich</surname><given-names>Nicholas E</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hfpnk21</institution-id><institution>Translational Genomics Research Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.24.22279131" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.24.22279131"/></front-stub><body><p>This study is of interest to epidemiologists and geneticists studying the association between telomere length and lung cancer risk. This work provides useful insight into risk factors for lung cancer. Overall, the results of this study are solid, as the genetic instrument used here is better powered and the battery of Mendelian randomization analysis makes this broad set of results convincing compared to previous work.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83118.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Banovich</surname><given-names>Nicholas E</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hfpnk21</institution-id><institution>Translational Genomics Research Institute</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Voight</surname><given-names>Ben</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>University of Pennsylvania</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.24.22279131">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.08.24.22279131v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Common genetic variations in telomere length genes and lung cancer: a Mendelian Randomization study and its novel application in lung tumor transcriptome&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Ben Voight (Reviewer #2).</p><p>As is customary in <italic>eLife</italic>, the reviewers have discussed their critiques with one another. What follows below is the Reviewing Editor's edited compilation of the essential and ancillary points provided by reviewers in their critiques and in their interaction post-review. Please submit a revised version that addresses these concerns directly. Although we expect that you will address these comments in your response letter, we also need to see the corresponding revision clearly marked in the text of the manuscript. Some of the reviewers' comments may seem to be simple queries or challenges that do not prompt revisions to the text. Please keep in mind, however, that readers may have the same perspective as the reviewers. Therefore, it is essential that you attempt to amend or expand the text to clarify the narrative accordingly.</p><p>Essential revision:</p><p>The reviewers provided a set of critiques that are manageable in scale. Please respond to all of the reviewer comments.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Figures are difficult to read as they are poor resolution.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. Resolution is not great on some of the figures – made reading them a little bit hard. I trust the authors will provide higher-resolution versions in the proofing phases!</p><p>2. Figure 1B – Not sure what this overall means/how to be interpreted – I think this is too much data plotted on the same figure for my taste.</p><p>3. I think the authors should create a supplementary table that enumerates the list of SNPs used for their instrument, along with annotated info about the SNP (pos, alleles, allele frequency), effect estimate, p-value report; then, for each SNP, the relevant outcome data of interest in the paper (effect sizes, se, P-value). That way, it is perfectly clear what SNPs are used and what estimated effects are used as input for MR experiments.</p><p>4. I'm a little confused about the colocalization analysis:</p><p>a. Suppl. Table 6: it looks to me like there are annotation mislabelling issues.</p><p>b. Also it isn't clear in this table which LTL loci have /any/ evidence of lung cancer association, i.e., PP1/2 vs. PP3.</p><p>For these, suggest checking the table and adding a column for the top lung cancer association (and SNP) in the interval tested by coloc.</p><p>c. But also confusing somewhat that there appear to be multiple TERT signals and those with colocalization but are basically on top of one another whilst still being LD independent (e.g., rs61748181 and rs33977403).</p><p>Overall here it looks like there may be some differences between genetic variants selected at this locus compared between Codd et al. and here. It could be these choices make sense and are reasonable, but might be worth looking back at differences to see if different choices drive the results they see.</p><p>5. In methods describing the Lung cancer data, are histologic data a complete subset of the overall data? It looks like there are shared controls (? a small limitation if so), but why is the number of controls in two strata greater than the overall? The cases totals are also less than overall, are 'lost' cases here simply because a subtype isn't specified? Perhaps the authors can clarify this a bit in methods.</p><p>6. Given the sample size differences, what effect sizes were the authors powered to observe in the Lung Squamous cell carcinoma and Lung Small Cell Carcinoma groups? Should this be interpreted as a false negative due to lack of power OR were the authors reasonably powered to observe (say) the estimated effect size overall in the univariate or epidemiological correlation data (but failed to see that effect), consistent with apparent heterogeneity in these strata?</p><p>7. As the author indicates, the MR Egger results (Table S2) suggest substantial 'negative' confounding. This is a little confusing – in my experience, I have seen negative confounding for sure previously, but this is probably some of the stronger effects that I've seen before. I don't have any great advice about how to look at this in detail, other than perhaps through MVMR, or by looking carefully at the IV regression plot to see if there are outliers that are somehow strongly influencing MR-Egger.</p><p>8. Inclusion of an epidemiological correlational data baseline between LTL &gt;&gt; lung cancer to compare to the MR estimates would also add value.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Common genetic variations in telomere length genes and lung cancer: a Mendelian Randomization study and its novel application in lung tumour transcriptome&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by a Senior Editor and a Reviewing Editor.</p><p>The manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>New revisions required:</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>The authors have responded to most comments reasonably.</p><p>However, I still have some concerns about the given report. I know the collection of these points below are a little extra work -- I am honestly not trying to &quot;add on&quot; but do think these experiments are important to bring out the robustness of the author's claim, add value to the extant literature, and interpretation at these key points around the MR they describe.</p><p>1. First, focused around my original comment #2 (in the author's response, their point #6) on multivarible MR experiments. To my point that there are actually multiple potential confounders – including smoking, BMI, and waist-hip ratio that could potentially confound the interpretation that LTL explains the lung-cancer associations, the authors performed one experiment focused on BMI. They note that for each cancer trait there appears to be no impact on their primary association between LTL and Lung cancer data when considering BMI.</p><p>However, what they present is still a bit inadequate from my point of view, in the following ways.</p><p>1a. The authors perform a form of this MVMR which is a little 'less' good in my view for this -- they build a new instrument based on SNPs ascertained for association with BMI, and then include that in the MVMR regression analysis. This is not how I would do this -- this result describes a &quot;joint&quot; model for the effect of exposures (BMI, LTL) on outcome (Lung cancer). This version does not regress out any potential association of the SNPs *selected for association with LTL* has with the potential confounder. In this case, if the LTL variants had strong association with the confounder (e.g., BMI), I don't think that this would be fully accounted for.</p><p>Instead, the authors should take the n=144 SNPs selected for the LTL instrument, identify associations from extant data with the putative confounder of interest (e.g., BMI), create an instrument for the genetically mediated effects of that confounder, and include that as an instrument for covariate confounding.</p><p>I.e., &quot;regress out&quot; any effect that the LTL instrument might have on the confounder, and report adjusted effects of the LTL instrument on cancer risk.</p><p>Yes: this may NOT be a very strong instrument for the confounder -- but that's not the point here. The point is to determine the effect of genetically mediated LTL on cancer adjusting for any effect that instrument the authors built for it has on the confounder.</p><p>1b. Furthermore, considering a single confounder here is really suboptimal. As indicated in the previous comments and as the authors know, smoking behavior and other anthropomorphic measures (e.g., waist-hip ratio) are also correlated with everything here. So the authors should really consider an expanded list of confounders for this to be clearly convincing that LTL really does operate as a causal exposure independently of these other risk factors.</p><p>1c. In addition to experiments that are pairwise, they should also consider performing an experiment with all potential confounders included in the model</p><p>Cancer ~ LTL + BMI + WHR + SMOKING + …..</p><p>I.e., can the authors convincingly demonstrate that the observed relationship between LTL and these lung cancer outcomes is not explained by a battery of obvious confounders individually or as a collective</p><p>1d. As suggested earlier – I think value and novelty would be added if the authors really took this on and explored this space a bit more -- look hard and think carefully about what confounders really *COULD* explain this result and work hard to refute that those could explain these observations</p><p>I do think a robust set of experiments should be included in the primary report beyond smoking, either way (in the supplement). I think the authors report the BMI result in the rebuttal response to me but don't add those back to the paper. I'd honestly like to see a healthy version of that added to the paper, but that's my taste on this point.</p><p>2. On my previous point #4 (in the rebuttal, point #8), I asked the authors to consider a subset MR analysis which focused on those where the genes/signals map quite obviously on known telomere length biology and represent some of the strongest signals. The authors respond that they can't actually do this analysis, suggesting that using the data for co-localization somehow invalidates an MR sub-set analysis.</p><p>I thought about this a little bit and while I admit that I can be daft sometimes I honestly do not understand what basis – empirical or theoretical – this argument has to somehow drive positive or negative biases here, i.e., why they need an &quot;out of sample&quot; set to perform the MR after they used this data to perform colocalization. If there's specific literature or reasoning the authors would like to articulate this in more detail, that would certainly be appreciated!</p><p>My intuition is that this actually isn't much of an issue -- performing subset analyses for different reasons (biological or otherwise) is actually pretty reasonable and there are MR methods that actually try to cluster / subset instruments used.</p><p>This all goes to interpretation and as a sensitivity analysis -- if the result is driven entirely by variation at TERT, TERC, OBFC1 but not obviously by other variation that influences telomere length, then I personally think that is worth trying to understand and report. Analytically, this is a *trivial* experiment to perform in the UVMR space.</p><p>3. Regarding the rebuttal point #13, which involved my point about power for discovery in the subset given the sample size, the authors state that there are sample size difference but then write something about confidence intervals overlapping that I don't quite understand.</p><p>What I think the authors SHOULD do with respect to the tumor histology analysis is to report a credible set based on power calculation which determine what range of causal effect sizes the Lung Squamous CC and Lung Small CC were powered to discover (at an α type-1 error rate) of 5% and/or 1%, say, given the instruments used and sample sizes involved here.</p><p>This is actually a very easy thing to do analytically with some assumptions – back of envelope -- you could check out what formula I pulled together in PMID: 25165093 to get the distribution under the alternative; I believe there are also MR power calculators out there as web tools. You easily do this with some R calculations in a straight forward way.</p><p>I think the authors should be able to articulate is that effect sizes (say) of OR=1.6 or better would be discoverable in those lung cell subsets that basically catch the null hypothesis. Or, that those sets were well powered to discover ORs that were even smaller than that. This would then give you a quantitative assessment that this isn't simply a false-negative result, but that there is putative heterogeneity here. But if they are small enough that they AREN'T particularly well powered, then that's a pretty important interpretive point on this plot.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83118.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revision:</p><p>The reviewers provided a set of critiques that are manageable in scale. Please respond to all of the reviewer comments.</p><p>Reviewer #1 (Recommendations for the authors):</p><p>Figures are difficult to read as they are poor resolution.</p></disp-quote><p>We apologize for these lower resolution figures. All figures have been updated in higher resolution (600 dpi) in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. Resolution is not great on some of the figures – made reading them a little bit hard. I trust the authors will provide higher-resolution versions in the proofing phases!</p></disp-quote><p>We apologize for these lower resolution figures. All figures have been updated in higher resolution (600 dpi) in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>2. Figure 1B – Not sure what this overall means/how to be interpreted – I think this is too much data plotted on the same figure for my taste.</p></disp-quote><p>The figure 1B sought to provide insights on the possible reasons why there were not genome-wide genetic correlations observed between lung adenocarcinoma (or any lung cancer histological subtype) and genetically predicted leukocyte telomere length.</p><p>We are highlighting in this figure that only a small subset of LTL variants is associated with longer telomere length and higher risk of lung adenocarcinoma development on one hand, but variants also related to lung cancer risk such as smoking behavior traits are associated in the opposite direction. We speculated that a possibility for the lack of genetic correlation between LTL and lung cancer may be these opposing effects that may explain the lack of global genetic correlation between TL and lung adenocarcinoma.</p><p>We have re-worded the figure legend to make this figure clearer to the reader and further highlighted this aspect and link to this figure in the discussion.</p><disp-quote content-type="editor-comment"><p>3. I think the authors should create a supplementary table that enumerates the list of SNPs used for their instrument, along with annotated info about the SNP (pos, alleles, allele frequency), effect estimate, p-value report; then, for each SNP, the relevant outcome data of interest in the paper (effect sizes, se, P-value). That way, it is perfectly clear what SNPs are used and what estimated effects are used as input for MR experiments.</p></disp-quote><p>Thanks, this reviewer for the suggestion. We added supplementary file 1a listing all the SNPs used as LTL instruments in the current study in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>4. I'm a little confused about the colocalization analysis:</p><p>a. Suppl. Table 6: it looks to me like there are annotation mislabelling issues.</p></disp-quote><p>We apologize for the annotation mislabelling issues, and the table was corrected in the revised manuscript. The genetic variants were annotated using ANNOVAR tool and the dbSNP150 database in the supplementary file 1g of the revised manuscript. Of the 144 SNPs from the LTL instrument, 11 were replaced by proxies (R<sup>2</sup>&gt;0.8, whenever possible, in European population 1000 genomes) in the current study because they were missing in the lung adenocarcinoma GWAS summary statistic. A column was added to specify the proxies in the supplementary file 1g of the revised manuscript.</p><disp-quote content-type="editor-comment"><p>b. Also it isn't clear in this table which LTL loci have /any/ evidence of lung cancer association, i.e., PP1/2 vs. PP3.</p><p>For these, suggest checking the table and adding a column for the top lung cancer association (and SNP) in the interval tested by coloc.</p></disp-quote><p>We have included the columns with PP1/PP2/PP3 in the supplementary file 1g of the revised manuscript. Only one locus (<italic>RETL1</italic>) displayed high PP3 (0.99). We have added the information of this PP3 levels in our results describing the lack of colocalisation for the variants within <italic>RTEL1</italic> locus (PP4=0) in the result section of the revised manuscript (page 12, lines 260-264).</p><disp-quote content-type="editor-comment"><p>c. But also confusing somewhat that there appear to be multiple TERT signals and those with colocalization but are basically on top of one another whilst still being LD independent (e.g., rs61748181 and rs33977403).</p></disp-quote><p>Again, we apologise for the error in the genetic variant annotation in the former supp table S7/ current supplementary file 1g noted above. This has complicated again the interpretation relative to this point. Supplementary file 1g has been corrected in the revised version of the manuscript. Indeed, there seems to be multiple independent hits at <italic>TERT</italic> locus when using our filtering (r2&lt;0.01).</p><disp-quote content-type="editor-comment"><p>5. In methods describing the Lung cancer data, are histologic data a complete subset of the overall data? It looks like there are shared controls (? a small limitation if so), but why is the number of controls in two strata greater than the overall? The cases totals are also less than overall, are 'lost' cases here simply because a subtype isn't specified? Perhaps the authors can clarify this a bit in methods.</p></disp-quote><p>Indeed, histological subtype information was not available for all studies. We clarify this point in the revised manuscript (page 34, line 755).</p><disp-quote content-type="editor-comment"><p>6. Given the sample size differences, what effect sizes were the authors powered to observe in the Lung Squamous cell carcinoma and Lung Small Cell Carcinoma groups? Should this be interpreted as a false negative due to lack of power OR were the authors reasonably powered to observe (say) the estimated effect size overall in the univariate or epidemiological correlation data (but failed to see that effect), consistent with apparent heterogeneity in these strata?</p></disp-quote><p>Yes, there are differences in sample size and therefore the statistical power within lung cancer strata, nevertheless, the confidence intervals of squamous cell carcinoma and small cell carcinoma did not overlap, implying a distinct association rather than a lack of power.</p><disp-quote content-type="editor-comment"><p>7. Inclusion of an epidemiological correlational data baseline between LTL &gt;&gt; lung cancer to compare to the MR estimates would also add value.</p></disp-quote><p>Unfortunately, we do not have measured telomere length at baseline for most of the case series and we used the LTL MR instrument to infer it.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>The authors have responded to most comments reasonably.</p><p>However, I still have some concerns about the given report. I know the collection of these points below are a little extra work -- I am honestly not trying to &quot;add on&quot; but do think these experiments are important to bring out the robustness of the author's claim, add value to the extant literature, and interpretation at these key points around the MR they describe.</p><p>1. First, focused around my original comment #2 (in the author's response, their point #6) on multivarible MR experiments. To my point that there are actually multiple potential confounders – including smoking, BMI, and waist-hip ratio that could potentially confound the interpretation that LTL explains the lung-cancer associations, the authors performed one experiment focused on BMI. They note that for each cancer trait there appears to be no impact on their primary association between LTL and Lung cancer data when considering BMI.</p><p>However, what they present is still a bit inadequate from my point of view, in the following ways.</p><p>1a. The authors perform a form of this MVMR which is a little 'less' good in my view for this -- they build a new instrument based on SNPs ascertained for association with BMI, and then include that in the MVMR regression analysis. This is not how I would do this -- this result describes a &quot;joint&quot; model for the effect of exposures (BMI, LTL) on outcome (Lung cancer). This version does not regress out any potential association of the SNPs *selected for association with LTL* has with the potential confounder. In this case, if the LTL variants had strong association with the confounder (e.g., BMI), I don't think that this would be fully accounted for.</p><p>Instead, the authors should take the n=144 SNPs selected for the LTL instrument, identify associations from extant data with the putative confounder of interest (e.g., BMI), create an instrument for the genetically mediated effects of that confounder, and include that as an instrument for covariate confounding. I.e., &quot;regress out&quot; any effect that the LTL instrument might have on the confounder, and report adjusted effects of the LTL instrument on cancer risk. Yes: this may NOT be a very strong instrument for the confounder -- but that's not the point here. The point is to determine the effect of genetically mediated LTL on cancer adjusting for any effect that instrument the authors built for it has on the confounder.</p><p>1b. Furthermore, considering a single confounder here is really suboptimal. As indicated in the previous comments and as the authors know, smoking behavior and other anthropomorphic measures (e.g., waist-hip ratio) are also correlated with everything here. So the authors should really consider an expanded list of confounders for this to be clearly convincing that LTL really does operate as a causal exposure independently of these other risk factors.</p><p>1c. In addition to experiments that are pairwise, they should also consider performing an experiment with all potential confounders included in the model Cancer ~ LTL + BMI + WHR + SMOKING + … i.e., can the authors convincingly demonstrate that the observed relationship between LTL and these lung cancer outcomes is not explained by a battery of obvious confounders individually or as a collective.</p><p>1d. As suggested earlier – I think value and novelty would be added if the authors really took this on and explored this space a bit more -- look hard and think carefully about what confounders really *COULD* explain this result and work hard to refute that those could explain these observations.</p><p>I do think a robust set of experiments should be included in the primary report beyond smoking, either way (in the supplement). I think the authors report the BMI result in the rebuttal response to me but don't add those back to the paper. I'd honestly like to see a healthy version of that added to the paper, but that's my taste on this point.</p></disp-quote><p>We thank the reviewer for their thorough and detailed review of our methods. We would like to take this opportunity to clarify that the standard MVMR analysis does consider multiple instrumental variables. The analyses that we have performed indeed account for the associations of LTL instruments with other variables. These established methods are reviewed in detail here (PMID: 30535378) and we have added this citation to the methods for clarity.</p><p>For the BMI example, the inputs for the MVMR analyses were as follows:</p><p>Therefore, the output of the MVMR analysis is a reasonable test of the effect of LTL on lung cancer that conditions on the genetic associations between LTL instruments and BMI.</p><p>We focused our initial response using BMI as an MVMR analysis for an adiposity-related trait was specifically requested by the reviewer and we felt BMI was reasonable in that context.</p><p>We have now expanded this to other traits. These include MVMR analyses for LTL on lung cancer adjusting for waist-to-hip-ratio (WHR), HDL, total triglycerides, blood pressure, smoking, and alcohol intake. These expanded analyses did not result in any material change to our conclusions. We similarly fitted a multivariate model including multiple traits (LC~ LTL+BMI+CPD+drinksperWeek), which similarly noted no material difference to our conclusion that LTL is associated with lung cancer risk. We acknowledge the reviewers point that these results should be included in the manuscript. They were included as supplementary file 1g in the revised manuscript.</p><p>We similarly acknowledge the reviewers point that we cannot exclude a potential effect of an unknown confounder. As such, we included the following sentence in the Discussion section of the revised manuscript: “We used MVMR analysis (citation pubmed PMID: 30535378) to assess the potential that factors, such as BMI, smoking, alcohol use and other obesity related factors, may account for the association between LTL and lung cancer. While the influence of alternative unknown potential confounding factors cannot be excluded, the association of LTL with lung cancer risk was materially unaltered following adjustment for a range of potential confounders considered in our MVMR analyses.”</p><disp-quote content-type="editor-comment"><p>2. On my previous point #4 (in the rebuttal, point #8), I asked the authors to consider a subset MR analysis which focused on those where the genes/signals map quite obviously on known telomere length biology and represent some of the strongest signals. The authors respond that they can't actually do this analysis, suggesting that using the data for co-localization somehow invalidates an MR sub-set analysis.</p><p>I thought about this a little bit and while I admit that I can be daft sometimes I honestly do not understand what basis – empirical or theoretical – this argument has to somehow drive positive or negative biases here, i.e., why they need an &quot;out of sample&quot; set to perform the MR after they used this data to perform colocalization. If there's specific literature or reasoning the authors would like to articulate this in more detail, that would certainly be appreciated!</p><p>My intuition is that this actually isn't much of an issue -- performing subset analyses for different reasons (biological or otherwise) is actually pretty reasonable and there are MR methods that actually try to cluster / subset instruments used.</p><p>This all goes to interpretation and as a sensitivity analysis -- if the result is driven entirely by variation at TERT, TERC, OBFC1 but not obviously by other variation that influences telomere length, then I personally think that is worth trying to understand and report. Analytically, this is a *trivial* experiment to perform in the UVMR space.</p></disp-quote><p>We apologise if our initial response was not sufficiently clear. While MR approaches that cluster variants within genetic instruments can be used to identify biological relevant subgroups of genetic predictors (DOI:10.1093/bioinformatics/btaa778), the results generated by this method can be challenging to interpret.</p><p>In our study, the genetic variants included in the MR analyses that was used to estimate the association of LTL with lung cancer risk have been associated with LTL (at least to genome wide significance) in an independent large GWAS (Codd et al. NG Nat Genet 2021). We subsequently used COLOC to highlight loci that have a particularly strong evidence of a shared causal association between LTL and lung cancer risk to enrich our understanding of the association of LTL with lung cancer. Our study has not sought to identify a subset of loci that predict LTL that are not associated with lung cancer risk.</p><p>We feel that MR analysis based on the stratified MR instrument (COLOC+ <italic>vs.</italic> COLOC-) would greatly complicates the interpretation of the results. Our concern is that to successfully estimate colocalisation, the variants of interest should be associated with both traits (i.e. LTL and lung cancer), particularly when conservative priors are used. By creating an MR instrument based on variants that are COLOC+, we are therefore selecting variants that are strongly associated with lung cancer in this dataset. As such, if that MR instrument was then re-applied into the same dataset, we expect that the instrument will return an estimate biased upwards due to how we selected the variants. We have created a MR instrument based on COLOC+ variants (n=12, variance in LTL explained of 1.05%) and applied that COLOC+ instrument in an MR analysis within our lung cancer dataset. This analysis is presented in the table below. The MR estimates using the COLOC+ instrument had a larger association with lung cancer risk (OR = 3.48 for lung adenocarcinoma (table below)) compared to MR instrument using all variants associated with LTL (OR = 2.43 for lung adenocarcinoma (figure 2)). However, in line with our concerns above, it is unclear to us if this increase in magnitude of association is driven by anything other than the expected greater strength of association for contributing variants and lung cancer risk provoked by the in-sample selection of these variants. We feel that an independent sample would be required to distinguish potential bias from a true biological difference from the effects of the COLOC+ MR instrument, which did not fall within the remit of our study.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>Exposure</th><th>Outcome</th><th>Method</th><th>P</th><th>OR</th><th>LCI</th><th>UCI</th></tr></thead><tbody><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Cancer</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">3.93E-06</td><td align="left" valign="top">2.21</td><td align="left" valign="top">1.58</td><td align="left" valign="top">3.10</td></tr><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Adenocarcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">2.91E-07</td><td align="left" valign="top">3.48</td><td align="left" valign="top">2.16</td><td align="left" valign="top">5.60</td></tr><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Squamous Cell Carcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.427</td><td align="left" valign="top">1.25</td><td align="left" valign="top">0.72</td><td align="left" valign="top">2.19</td></tr><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Small Cell Carcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.691</td><td align="left" valign="top">0.822</td><td align="left" valign="top">0.31</td><td align="left" valign="top">2.19</td></tr><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Ever Smokers</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.008</td><td align="left" valign="top">1.79</td><td align="left" valign="top">1.16</td><td align="left" valign="top">2.74</td></tr><tr><td align="left" valign="top">Telemore Length (Colocalised SNPs)</td><td align="left" valign="top">Lung Never Smokers</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.122</td><td align="left" valign="top">3.01</td><td align="left" valign="top">0.74</td><td align="left" valign="top">12.20</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Cancer</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">2.36E-08</td><td align="left" valign="top">1.51</td><td align="left" valign="top">1.31</td><td align="left" valign="top">1.74</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Adenocarcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">5.85E-15</td><td align="left" valign="top">2.38</td><td align="left" valign="top">1.91</td><td align="left" valign="top">2.96</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Squamous Cell Carcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.293</td><td align="left" valign="top">0.89</td><td align="left" valign="top">0.72</td><td align="left" valign="top">1.10</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Small Cell Carcinoma</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">0.852</td><td align="left" valign="top">1.03</td><td align="left" valign="top">0.76</td><td align="left" valign="top">1.39</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Ever Smokers</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">8.35E-06</td><td align="left" valign="top">1.44</td><td align="left" valign="top">1.23</td><td align="left" valign="top">1.69</td></tr><tr><td align="left" valign="top">Telemore Length (Non-Colocalised SNPs)</td><td align="left" valign="top">Lung Never Smokers</td><td align="left" valign="top">Inverse variance weighted</td><td align="left" valign="top">1.03E-03</td><td align="left" valign="top">1.85</td><td align="left" valign="top">1.28</td><td align="left" valign="top">2.66</td></tr></tbody></table></table-wrap><p>As suggested by the reviewer, an alternate approach could be the stratification of variants based on biological rational, limiting to genes encoding proteins described in telomere maintenance, for example. However, in this instance, we have performed the COLOC analysis and based on those COLOC results, we have already noted that telomere maintenance genes are those that tend to colocalise (Pg 15 lines 328-330). Therefore, a MR instrument based on the variants located at or near genes involved in telomere maintenance may also be potentially biased because of the observations we have already made.</p><p>We also have concerns about variants in the COLOC(-) strata. Here, we might expect a result to be estimates biased downwards (i.e. we could be selecting within this data, a set of variants that are less strongly associated with lung cancer). However, this isn’t that straight forward as COLOC is a generally conservative method and, as stated previously, we employed relatively strict priors. Additionally, COLOC can be a less efficient estimator of shared causal loci where multiple causal variants exist in a region but where only a subset are shared between two or more traits. As such, many loci associated with LTL but without strong evidence for colocalisation in our study may be associated with lung cancer. Moreover, a large proportion of variation in LTL is explained by COLOC(-) strata variants (n=132, variance explained of 2,45%). MR analyses using the COLOC(-) strata variants described in table below do estimate a strong association between LTL ad lung cancer. For these reasons, we feel that interpreting results based on genetic instruments stratified by COLOC status is very challenging for a reader.</p><p>We appreciate this reviewer’s point of view and thank them for their input. However, for the complexities related to how we have employed COLOC subsequent to our MR analysis outlined above, we prefer to be conservative and limit our analysis to MR instruments selected from the large LTL from a large GWAS of telomere length.</p><p>We highlight the limitations of the COLOC approach (discussion lines 328-329) and have adapted this text further for clarity.</p><p>“Our colocalisation approach is generally more conservative and may fail to accurately determine the posterior probability for shared genetic signals in the presence of multiple independent associations in a given locus (45) and we stress that many of the variants that are COLOC negative are likely to associated with lung cancer. Indeed, which may be a reasonable explanation for the lack of colocalisation observed at <italic>RTEL1</italic> locus”.</p><disp-quote content-type="editor-comment"><p>3. Regarding the rebuttal point #13, which involved my point about power for discovery in the subset given the sample size, the authors state that there are sample size difference but then write something about confidence intervals overlapping that I don't quite understand.</p><p>What I think the authors SHOULD do with respect to the tumor histology analysis is to report a credible set based on power calculation which determine what range of causal effect sizes the Lung Squamous CC and Lung Small CC were powered to discover (at an α type-1 error rate) of 5% and/or 1%, say, given the instruments used and sample sizes involved here.</p><p>This is actually a very easy thing to do analytically with some assumptions – back of envelope -- you could check out what formula I pulled together in PMID: 25165093 to get the distribution under the alternative; I believe there are also MR power calculators out there as web tools. You easily do this with some R calculations in a straight forward way.</p><p>I think the authors should be able to articulate is that effect sizes (say) of OR=1.6 or better would be discoverable in those lung cell subsets that basically catch the null hypothesis. Or, that those sets were well powered to discover ORs that were even smaller than that. This would then give you a quantitative assessment that this isn't simply a false-negative result, but that there is putative heterogeneity here. But if they are small enough that they AREN'T particularly well powered, then that's a pretty important interpretive point on this plot.</p></disp-quote><p>Thank the reviewer for this fair suggestion. We performed power calculations to determine the range of LTL causal effects on lung cancer that we are adequately powered to detect, and report these results in Supplementary Figure 2—figure supplement 1 (panel B) and on pages 11 and 18 of the revised manuscript. As seen in Figure 2—figure supplement 1b, our study has &gt;80% power to detect rather modest effects (OR~1.20) for lung cancer overall, adenocarcinoma, and squamous cell carcinoma. For less common subtypes, such as small cell carcinoma and lung cancer in never smokers, we 80% power to detect OR~1.40 and OR~1.50, respectively.</p></body></sub-article></article>